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Abstract 
 
 Women infected with the human immunodeficiency virus are at increased risk 
for developing cervical cancer. Current guidelines reflect that Pap smears should be 
performed twice during the first year after diagnosis with HIV and annually thereafter. 
However, women with HIV are not obtaining Pap smears per the current guidelines. The 
purpose of this study was to evaluate HIV-infected women’s attitudes toward cervical 
cancer and cervical cancer screening. The research design is an exploratory, cross-
sectional, quantitative design. The sample of convenience consisted of participants 
recruited from two ambulatory HIV clinics in Florida. Attitudes were assessed using 
Champion’s Health Belief Model and Self-efficacy scales. Knowledge was evaluated 
with an updated HPV/Cervical Cancer Knowledge scale. Sociodemographic variables 
were assessed using a Demographic Data form. The results indicate that HIV-infected 
women in the study were not knowledgeable about HPV or cervical cancer. They did not 
perceive that cervical cancer was serious, nor did they feel that they were susceptible to 
cervical cancer. Overall, HIV-infected women were confident in their ability to request a 
Pap smear, and they perceived fewer barriers and more benefits to Pap smears. Despite, 
perceptions of fewer barriers and more benefits a chart review revealed that 
approximately 43% of the study participants received a Pap smear during the past year. 
Perceived barriers was a significant predictor of Pap smear adherence (OR = 0.93, CI: 
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0.90 to 0.96, p < .01). Findings from the exploratory study provide important information 
to clinicians and researchers that will assist in the development of effective interventions 
to increase Pap test adherence. Additional research is needed to further understand factors 
that influence cervical cancer screening in this at-risk population. 
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Chapter One: Introduction 
 
 Human Immunodeficiency Virus (HIV)-infected women are at an increased risk 
for developing cervical dysplasia and cancer as a result of Human Papillomavirus (HPV) 
-infection (ACOG, 2010; Tello et al., 2010; Aberg et al., 2009) because of their 
compromised immune systems. The incidence and prevalence of HPV are high in HIV-
infected women, especially those infected with high-risk types of HPV [11, 16, 18, 33, 
51, 52, 53, 58 and 61] (De Vuyst, Lillo, Broutet & Smith, 2008; Clifford, Goncalves & 
Franceschi, 2006). It is estimated that 12,700 women develop cervical cancer annually, 
and approximately 4,200 women die as a result of cervical cancer (National Cancer 
Institute [NCI], 2011; American Cancer Society [ACS], 2011). The most common cause 
of cervical cancer is persistent infection with high-risk types of the HPV (NCI, 2011). 
Precancerous cells caused by HPV can develop into invasive cervical cancer if the body’s 
immune system does not clear the virus, the precancerous cells are not detected or the 
precancerous cells are left untreated (NCI, 2011).  In the early 1900s, cervical cancer was 
the leading cause of death in women but the introduction of Papanicolaou (Pap) testing 
drastically decreased mortality and morbidity rates secondary to cervical cancer (ACS, 
2011). The Human Papillomavirus can be detected by HPV deoxyribonucleic acid (DNA) 
testing, and precancerous cells (cervical dysplasia) can be detected by Pap testing (NCI, 
2011). Cervical cancer screening via Pap testing is the recommended screening tool for 
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detecting cervical dysplasia (ACS, 2011; NCI, 2011; The American College of Obstetrics 
and Gynecology [ACOG], 2010). 
 Persistent infection with HPV is common in women infected with HIV including 
high-risk types and infection with multiple types which increases the risk of progression 
to cervical cancer; thereby, making frequent Pap testing vital (De Vuyst et al., 2008; 
Clifford et al., 2006). Current ACOG guidelines suggest conducting Pap testing every six 
months during the first year after diagnosis or during the first year in care and annually 
thereafter in women infected with HIV (ACOG, 2010).  
However, HIV-infected women are not receiving Pap testing according to the 
ACOG guidelines (Leece, et al., 2010). Studies have indicated that 19% to 25% of HIV-
infected women had not received their annual Pap smear during the previous year 
(Rahangdale, Sarnquist, Yavari, Blumenthal & Israelski, 2010; Tello et al., 2010; Oster, 
Sullivan & Blair, 2009; Stein et al., 2001; Solomon et al., 1998), and about 75% had not 
received the second recommended Pap test during their first year in care (Logan, 
Khambaty, D’Souza & Menezes, 2010). Two other studies concluded that as many as 
47% of HIV-infected women were not obtaining Pap smears annually (Baranoski et al., 
2011; Bazargan, Bazargan, Farooq & Baker 2004). Many reasons have been cited for 
lack of Pap smear adherence.  
Pain, lack of social support, lack of knowledge, lack of perceived susceptibility, 
and previous negative experiences with  healthcare providers have been identified as 
factors associated with failure to adhere to Pap testing among women not infected with 
HIV (Daley et al., 2011; Ackerson, Pohl & Low, 2008; Austin, Ahmad, McNally & 
Stewart, 2002).  Fear of cancer diagnosis and of discrimination, language barriers, 
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cultural beliefs, fatalistic attitudes and embarrassment were cited as factors that were seen 
as barriers to cervical cancer screening (Daley et al., 2011; Tracy, Lydecker & Ireland, 
2010; Watts et al., 2009; Lee-Lin et al., 2007; Warren, Londono, Wessel & Warren, 
2006; Austin et al., 2002). Age data were mixed (Tracy et al., 2010; Watts et al., 2009; 
Blackwell, Martinez & Gentleman, 2007; Lee-Lin et al., 2007; Datta et al., 2005; Hewitt, 
Devesa & Breen, 2004). Lack of insurance was documented as another factor that serves 
as a barrier (Daley et al., 2011; Peterson et al., 2008; Lee-Lin et al., 2007; Warren et al., 
2006: Gorin & Heck,  2004; Hewitt et al., 2004). Being of a specific ethnic group and 
having less than high school education were associated with poor Pap test adherence 
(Tracy et al., 2010; Peterson et al., 2008; Blackwell et al., 2007; Coughlin, King, 
Richards & Ekwueme, 2006; Datta et al., 2005; Hewitt et al., 2004). Perceiving more 
barriers and fewer benefits was associated with poor adherence (Tracy et al., 2010). 
Transportation to the clinic was also cited as a factor (Daley et al., 2011). Obesity as 
determined by body mass index (BMI) was a documented barrier, but obesity data were 
mixed (Blackwell et al., 2007; Ferrante, Chen, Crabtree & Wartenberg, 2007; Datta et al., 
2005).  
 Factors that were associated with poor adherence to cervical cancer screening in 
women infected with HIV include receiving a pelvic exam by a provider not managing 
the woman’s HIV and low CD4+ T lymphocyte count (less than 200) (Baranoski et al., 
2011; Rahangdale et al., 2010; Logan et al., 2010; Oster et al., 2009; Tello et al., 2008; 
Shah et al., 2006; Stein et al., 2001).  Substance abuse, especially intravenous drug use, 
lack of child care, insufficient social support, and lack of knowledge were identified as 
factors that negatively affected Pap smear adherence in women infected with HIV (Logan 
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et al., 2010; Tello et al., 2010; Tello et al. 2008; Andrasik, Rose, Pereira & Antoni, 2008; 
Keiser et al., 2006). Negative attitudes toward providers, lack of providers’ knowledge of 
current ACOG guidelines, poor provider-patient communication, extended wait times, 
lack of continuity of care, and discomfort during Pap test were identified as factors that 
hindered Pap testing in HIV-infected women (Logan et al., 2010; Andrasik et al., 2008; 
Bazargan et al., 2004). Economic barriers including lack of insurance, financial 
constraints, and lack of transportation influenced Pap testing (Tello et al., 2010; Tess & 
Hackley, 2010; Andrasik et al., 2008; Bazargan et al., 2004). Pap testing was affected by 
psychological barriers including fear of knowing the results, denial, depression and low 
self-esteem (Tello et al., 2010; Andrasik et al., 2008). Data regarding the association of 
age and Pap test adherence is mixed (Baranoski et al., 2011; Logan et al., 2010; Tello et 
al., 2010; Tello et al., 2008; Oster et al., 2009; Keiser et al., 2006; Shah et al., 2006; 
Bazargan et al., 2004). Having an HIV viral load of greater than 400 was associated with 
not obtaining a Pap smear during the previous year (Keiser et al., 2006; Shah et al., 
2006). Having less education, inclement weather, and forgetting appointments were 
factors that negatively affect Pap smear adherence (Tello et al., 2010; Keiser et al., 2006). 
Not being white and being obese also were associated with poor Pap smear adherence in 
HIV-infected women (Tess & Hackley, 2010; Keiser et al., 2006; Tello et al., 2008; 
Bazargan et al., 2004).  
 Andrasik and colleagues (2008) interviewed HIV-infected African American 
women regarding barriers to cervical cancer screening, and several women reported 
having a lack of knowledge about reproductive health. During a thorough review of the 
literature, no studies were found that assessed knowledge of cervical cancer and Pap 
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testing in women infected with HIV. No studies were found that examined perceived self-
efficacy in discussing cervical cancer screening with a healthcare provider or being able 
to request Pap testing. No studies have evaluated perceived susceptibility, perceived 
seriousness, perceived benefits, or perceived barriers to cervical cancer screening in HIV-
infected women; therefore, making this proposed study unique and an important addition 
to the existent body of knowledge.   
Purpose  
The purpose of this study was to evaluate HIV-infected women’s knowledge of 
and perceived susceptibility to cervical cancer, and their perception of the seriousness of 
cervical cancer. Further, the study assessed their perceived self-efficacy, benefits, and 
barriers to cervical cancer screening. In addition, predictors of cervical cancer screening 
in HIV-infected women were evaluated.  
Specific Aims 
Aim one. Evaluated the relationship between Pap test adherence and the 
following variables in: a) Champion’s Health Belief Model Scale (CHBM) and b) 
Champion’s Self-efficacy (CSE) scale and c) HPV/cervical cancer knowledge scale.  
Aim two. Evaluated the relationships between the following variables in: CHBM, 
CSE, and knowledge scales, and selected sociodemographic variables. 
Aim three. Assessed the ability of the variables in CHBM, CSE, and knowledge; 
and select sociodemographic variables to predict Pap testing. 
Conceptual Framework 
 The Health Belief Model (HBM) provided the theoretical base for this study. The 
HBM was developed by psychologists in the U.S. Public Health Service in the 1950s as a 
6 
 
way to explain participation in medical prevention and disease detection programs 
(Glanz, Rimer & Viswanath, 2008 as cited in Hochbaum 1958; Rosenstock, 1960, 1974).  
The model was later expanded to explain the behavior of people in response to a medical 
diagnosis such as cancer (Glanz et al., 2008 as cited in Becker, 1974).  
 According to Glanz, Rimer and Viswanath (2008) the HBM predicts the reason(s) 
individuals take action to prevent, screen for and control illness; as in the case of Pap 
testing in HIV-infected women.  The HBM has been used to explain behaviors such as 
tuberculosis screening, breast cancer screening, colon cancer screening, and risky sexual 
behaviors (Glanz et al., 2008). A person’s beliefs, attitudes and perceptions about a 
disease determine their actions to seek methods to prevent, screen for and control a 
disease (Glanz et al., 2008). Intrapersonal factors such as knowledge, socio-economics 
issues and age influence health behaviors (Glanz et al., 2008). The constructs of the 
original HBM include perceived susceptibility, seriousness, benefits and barriers to a 
specific behavior with the addition of cues to action and health motivation in the 1970s 
and perceived self-efficacy in 1988. A valid instrument to measure cues to action does 
not exist, and the concept is difficult to study in a survey (Glanz et al., 2008). However, 
cues to action was evaluated in this study. 
 To help clarify the model, the definitions of the four original constructs, perceived 
susceptibility, perceived seriousness, perceived benefits and perceived barriers to a 
specific preventive action, are presented in the subsequent paragraph (Glanz et al., 2008). 
The HBM implies that an individual’s perception of his/her susceptibility to a disease 
coupled with his/her belief that the disease has potentially serious consequences 
(perceived seriousness) equals the perceived threat which leads to a behavior such as Pap 
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testing. If the person believes that behaviors such as Pap testing are beneficial and 
outweigh his/her perceived barriers, then he/she is more likely to adopt the new behavior. 
The concept cues to action did appear in earlier diagrams of the HBM and it is considered 
as a modifying variable (Glanz et al., 2008). Cues to action are events, people or things 
that encourage people to change their behavior (Glanz et al., 2008). Examples of agents 
of cues to action include family, friends, media, and health care providers (Glanz et al., 
2008). Other modifying variables include age, gender, ethnicity, personality, 
socioeconomics, knowledge and motivation (Glanz et al., 2008). Health motivation was 
introduced by Becker (1974) (as cited in Champion, 1984). Health motivation is a 
concern about health (Champion, Skinner & Menon, 2005; Champion, 1984). Self-
efficacy was added to the original four concepts in 1988 (Glanz et al., 2008). Self-
efficacy is an individual’s belief that he/she can successfully accomplish a behavior 
(Bandura, 1977). In combination with perceived susceptibility and seriousness, a person 
must feel that he/she is capable of carrying-out a specific behavior and that the benefits of 
the behavior outweigh the barriers. In addition, cues to action such as reminder letters or 
reminder phone calls could lead to a specific outcome behavior. Figure 1.1 is a depiction 
of a modified version of the HBM (Glanz et al., 2008).  
Theoretical Definitions 
 Perceived susceptibility. The belief of a person about his/her chances of getting a 
condition or disease (Glanz, Rimer and Viswanath, 2008).  
 Perceived seriousness. An individual’s belief about the severity of a disease 
(Glanz et al., 2008).  
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Figure 1 Modified Health Belief Model 
 Perceived benefits. A person’s belief that the new behavior will reduce his/her 
risk of a disease (Glanz et al., 2008; Champion 1993) 
 Perceived barriers. The belief of a person about obstacles that may prevent them 
from a specific action (Glanz et al., 2008). 
 Perceived self-efficacy.  A person’s belief or confidence in his/her ability to take 
action or adapt a specific behavior (Glanz et al., 2008; Champion, Skinner & Menon, 
2005).  
 Cues to action. Factors that will trigger a person to adopt a new behavior (Glanz 
et al., 2008).   
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 Health motivation. A state of concern about general health issues (Champion, 
1984). 
 HPV/Cervical cancer knowledge. The information that an individual knows 
about the causes, risk factors, mode of transmission, screening tools and methods of 
prevention regarding cervical cancer.   
 Adherence to guidelines. In 2010, the American College of Obstetrics and 
Gynecology (ACOG) developed guidelines for gynecologic care specific to women 
infected with HIV. The guidelines state that HIV-infected women must receive two Pap 
test the first year after diagnosis and then Pap testing every year (ACOG, 2010). 
Significance 
  Infection with HPV increases HIV-infected women’s risk of developing cervical 
dysplasia; particularly, if the virus is left untreated (ACOG, 2010; Tello et al., 2010; 
Aberg et al., 2009). A significant number of studies have established that certain barriers 
exist as failures to adhere to pap testing in the general population.  However, limited 
research addresses factors affecting cervical cancer screening in HIV infected women. 
Clinicians could identify patients at risk for poor Pap test adherence with a better 
understanding of HIV-infected women’s perception of their susceptibility and 
vulnerability to developing cervical cancer; in addition to, the benefits, barriers and 
knowledge of women infected with HIV, with regard to receiving cervical cancer 
screening. Based on the review of available research, clinicians are in need of 
information that can be used to identify factors affecting cervical cancer screening in HIV 
infected women. 
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Summary  
 Cervical cancer is caused by untreated cervical dysplasia or abnormal cervical cell 
changes which are commonly caused by HPV.  Pap testing is the recommended screening 
tool to detect cervical cell changes. HIV-infected women have an increased risk of 
developing cervical cancer and ACOG has released recommended cervical cancer 
screening guidelines which are different from the guidelines of women not infected with 
HIV. HIV-infected women are not receiving Pap testing at the recommended intervals 
and numerous barriers to receiving Pap testing have been documented. A survey study 
was proposed to evaluate factors that influence cervical cancer screening in HIV-infected 
women. The proposed study may enhance the knowledge of clinicians caring for HIV-
infected women and motivate researchers to assess interventions that will improve 
cervical cancer knowledge and awareness; as well as, eliminate or lessen barriers to 
cervical cancer screening. This research is important to clinicians, researcher and women 
infected with HIV.  
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Chapter Two: Literature Review 
 
Note to Reader 
 Portions of the review of literature have been previously published (Chapman 
Lambert, 2012) and are utilized with permission of the publisher. 
 
 Chapter two of the dissertation proposal is a presentation of the review of 
literature concerning the human papillomavirus (HPV), cervical cancer, cervical cancer 
screening guidelines for HIV-infected women and sociodemographic factors that 
influence cervical cancer screening. In addition, information is presented about the 
perceived susceptibility, severity, benefits, barriers and self-efficacy to cervical cancer 
and cervical cancer screening. The information presented about HPV and cervical cancer 
was retrieved from the following websites: ACS, AIDS Healthcare Foundation, CDC, 
NCI and WHO. The following search engines were utilized to search for articles: 
CINAHL, PubMed and PsychINFO. Keywords in different combinations were used to 
retrieve articles: cervical cancer, screening, Pap smear, Pap test, prevention, barriers, 
HIV, AIDS, HBM, cervical dysplasia, and HPV. Additional articles were selected from 
the reference pages of studies identified in the initial search. The material presented 
builds a case for the significance of the proposed study.  
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Human Papillomavirus 
HPV is a group of more than 150 types of the virus, of which 40 are known to be 
sexually transmitted (CDC, 2010b; NCI, 2011a). The 40 viruses that are sexually 
transmitted can cause genital warts or cervical cancer. An infected person can transmit 
these viruses to his/her partner(s) via vaginal, anal, or oral sexual intercourse in the 
absence of symptoms and while using condoms (CDC, 2010b; NCI, 2011a). Genital HPV 
infections are common and usually occur and resolve without symptoms after a few years 
(NCI, 2011a). Alarmingly, HPV is so common that about 50% of Americans will be 
infected at some time in their lives (NCI, 2011a). Persistent infection with HPV can cause 
precancerous cells (cervical dysplasia), and, when left untreated, cancers of the vagina, 
vulva, penis, anus, and oropharynx may develop (CDC, 2010b). Women infected with 
HIV are more likely to be infected with multiple types of HPV, are less likely to have the 
virus cleared by their weakened immune systems, and are more likely to develop cancer 
(Clifford, Goncalves, & Franceshi, 2006; De Vuyst, Lillo, Broutet, & Smith, 2008).  
HPV Vaccines 
 In an effort to prevent cervical cancer, the U. S. Food and Drug Administration 
approved two vaccines, Gardasil® and Cervarix®. Both vaccines are effective against 
high-risk HPV types 16 and 18 (CDC, 2011). In addition, Gardasil® is effective against 
HPV types 6 and 11, which are responsible for most genital wart infections (CDC, 2011). 
Gardasil® is licensed for females and males ages 9 to 26 years and Cervarix® is licensed 
for females ages 9 to 26 years (CDC, 2011). The CDC (2011) recommends vaccine 
administration beginning at ages 11 or 12 years, with 9 years being the minimum age 
allowed. The CDC (2011) has emphasized that HPV vaccines do not cure or treat existing 
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infections, but women with a history of cervical dysplasia (abnormal Pap result) should 
receive the vaccine in accordance with the current CDC guidelines.  
Cervical Cancer  
Cervical cancer starts at the lower part of a woman’s uterus (NCI, 2008). There 
approximately 15 types of high risk HPV, with HPV 16 and 18 being the most common, 
Persistent infections with high-risk HPV types can progress to cervical cancer (NCI, 
2011a). Globally, more than 500,000 women have been estimated to be diagnosed with 
HPV-related cervical cancer annually with 80% of cases occurring in developing 
countries (WHO, 2011). The NCI (2011a) has predicted that each year more than 12,000 
women in the United States will be diagnosed with HPV-related cervical cancer and more 
than 4,000 will die. Risk factors for cervical cancer, in addition to HPV, include using 
tobacco, being immune compromised, giving birth to three or more children, and being 
on oral contraception for more than 5 years (CDC, 2010a; NCI, 2011a). Women with 
early stage cervical cancer rarely have symptoms. It is not until the cancer progresses that 
women experience abnormal vaginal bleeding between menstrual periods, after 
intercourse, after menopause, or after pelvic examinations (NCI, 2011a). Cervical cancer 
screenings can detect abnormal cells or pre-cancerous cells early, allowing treatment to 
be initiated.  
Cervical Cancer in HIV-Infected Women 
Cervical cancer is considered an AIDS-defining cancer in individuals infected 
with HIV (AIDS Healthcare Foundation, 2008). Infection with HIV weakens the immune 
system leaving an individual vulnerable to a number of cancers (NCI, 2011b). The risk of 
cervical cancer in HIV-infected women is greater than the risk in uninfected women due 
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the immune system’s limited ability to fight HPV (AIDS Healthcare Foundation, 2008; 
ACOG, 2010; NCI, 2011b). The introduction of effective antiretroviral therapy (ART) 
has decreased the incidence of Kaposi’s sarcoma and non-Hodgkin’s lymphoma, but 
ART has not decreased the incidence of cervical cancer, and the reason for this is not 
well understood (NCI, 2011b). Women co-infected with HIV and HPV, with HPV-
related cervical cancer, and with CD4+ T lymphocyte counts less than 200 cells/mm3 
have a risk of poorer outcomes (AIDS Healthcare Foundation, 2008). Women with CD4+ 
T lymphocyte counts less than 50 cells/mm3 are at higher risk of the cervical cancer 
returning after treatment (AIDS Healthcare Foundation, 2008).  
Screening Guidelines in HIV-Infected Women 
Routine cervical cancer screenings with Pap test and follow-up treatment reduces 
mortality in all women. Secondary to higher incidences of cervical cancer in women 
infected with HIV, screening guidelines for HIV-infected women differ in frequency 
from those of uninfected women. Women infected with HIV should receive two Pap tests 
the first year after diagnosis or during the first year in care, and annually thereafter 
(ACOG, 2010). According to Armas and colleagues (2007), HIV-infected women also 
should receive at least two cervical cancer screenings, 6 months apart, after changing 
sexual partners, and annually thereafter if the results are normal. Cervical cancer 
screening should begin at age 21 (ACOG, 2009). It is appropriate to discontinue 
screening after age 65 in women who have had three or more negative Pap test in a row 
and in women without a history of abnormal test results in the previous 10 years (ACOG, 
2009). Women 65 years of age and older who are sexual active and have multiple sex 
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partners should continue to be screened per ACOG guidelines (ACOG, 2009). Clinicians 
should continue to conduct risk assessments after discontinuing screening (ACOG, 2009).  
Factors that Influence Cervical Cancer Screening 
 Many factors that affect cervical cancer screening are common to all women, but 
there are factors that solely affect HIV-infected women. Factors such as age, tobacco use, 
weight, race/ethnicity, education, economics, and risky sexual behaviors have been cited 
as affecting cervical cancer screening in all women. Serologic values such as HIV viral 
load and CD4+ T lymphocyte count are factors unique to women infected with HIV.  
Age. The majority of the articles agreed that older women were more likely to 
have poor Pap test adherence. A chart review of women ages 18 to 60 at a large urban 
HIV clinic revealed that older age was associated with inadequate Pap testing (Baranoski, 
Horsburgh, Cupples, Aschengrau, & Stier, 2011). Two hundred women attending the 
Johns Hopkins HIV clinic were surveyed about Pap test adherence and the results 
revealed that women 50 years of age and older were less likely to adhere to Pap testing 
(Tello et al., 2010). The Swiss HIV Cohort Study was developed to evaluate factors 
associated with frequency of gynecologic follow-up and cervical cancer screening. Older 
age was a predictor of fewer gynecologic examinations and Pap smears (Keiser et al., 
2006). As age increased, women were less likely to receive a Pap test (Oster, Sullivan, & 
Blair, 2009). Although older age has been consistently linked to poor Pap test adherence, 
one study conducted in an HIV clinic in San Mateo, California from January 2002 to 
December 2006 did not find an association between age and Pap test adherence 
(Rahangdale, Sarnquist, Yavari, Blumenthal, & Israelski, 2010).  
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In uninfected women, age data consistently found that older age was associated 
with poor Pap test adherence. In a sample of 255 lesbian women, older age was a 
predictor of adherence to routine cervical cancer screening (Tracy, Lydecker, & Ireland, 
2010). Women 30 years of age and older were less likely to report Pap smear screening in 
a study with 318 participants, ages 18 to 99 (Watts et al., 2009). Blackwell, Martine, and 
Gentleman (2007) conducted a secondary analysis using information from the Joint 
Canada/United States Survey of Health. The study examined Pap testing in Canadian and 
U.S. women during 2002 and 2003. Women ages 40 to 59 were less likely to be adherent 
to Pap testing than women ages 18 to 29. In women 40 years of age and older living in 
the southeastern United States, being 65 years of age or older was a factor that negatively 
influenced adherence to Pap testing (Peterson, Murff, Cul, Hargreaves, & Fowke, 2008). 
In 2005, using data from the National Health Interview Survey (NHIS), a sample of 
Latina women were surveyed about their use of Pap smears, and Latinas ages 50 years 
and older were less likely to have had a Pap test within the previous year (Gorin & Heck, 
2005). Among 230 African-American and Latino women living in an urban housing 
development in Los Angeles County, women ages 45 years and older were less likely to 
have had a Pap smear within the 12 months before the study (Bazargan, Bazargan, 
Farooq, & Baker, 2004). Another study analyzed the NHIS data and concluded that 
women of various ethnicities 65 years of age were less likely to be receiving Pap testing 
(Hewitt, Devesa, & Breen, 2004). Among Appalachian women, Pap testing was less 
common in women ages 65 years and older (Hall, Uhler, Coughlin, & Miller, 2002). 
From the information reported here, it can be inferred that older women are less likely to 
receive Pap testing than younger women.  
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Ethnicity/race. Ethnicity data were not consistent. A chart review of a large 
urban HIV clinic concluded that being White or Hispanic increased the odds of not 
having had a Pap test (Baranoski et al., 2011). In a prospective chart review conducted at 
the Johns Hopkins HIV Clinic from January 2002 to April 2006, women who were 
African American were less likely to attend gynecological appointments than Caucasian 
women (Tello et al., 2008). Among the Swiss study cohort, being of non-White ethnicity 
was associated with fewer Pap smears (Keiser et al., 2006).  
In uninfected women, being Black or African American has been shown to be a 
positive predictor of Pap test adherence (Bazargan et al., 2004; Blackwell et al., 2007; 
Hewitt et al., 2004; Peterson et al., 2008; Selvin & Brett, 2003). In a secondary analysis 
of the Southern Community Cohort Study, Peterson and colleagues (2008) examined Pap 
testing among women from low socioeconomic and education backgrounds. African 
American women had the highest cervical cancer screenings rates. In a sample of more 
than 5,000 U.S. women ages 18 years and older who participated in the Joint 
Canada/United States Survey of Health, non-Hispanic Black women were more likely to 
be compliant with Pap testing guidelines than non-Hispanic White women (Blackwell et 
al., 2007). Among the 13,745 women surveyed in the 2000 National Health Interview 
Survey, being African American relative to non-Hispanic White was associated with 
greater Pap test use (Hewitt et al., 2004).  
Tobacco use. Among HIV-infected women, research has indicated that women 
who smoke cigarettes are more like to have poor Pap test adherence. Being a current 
smoker was a predictor of fewer gynecologic examinations and Pap smears (Keiser et al., 
2006). An analysis of charts at Boston Medical Center found that HIV-infected women 
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who were current or former cigarette smokers had a decreased likelihood of having had a 
Pap test during 18 months of follow-up (Baranoski et al., 2011).  
Among uninfected women, data regarding the association of poor Pap smear 
adherence and cigarette use were mixed. Two research studies determined that cigarette 
smokers were more likely to comply with cervical cancer adherence (Blackwell et al., 
2007; Selvin & Brett, 2003). However, Hewitt and colleagues (2004) concluded that 
cigarette smokers were less likely to adhere to cervical cancer screening (Datta et al., 
2006). Datta and colleagues (2006) analyzed data from the Black Women’s Health Study, 
which included approximately 59,000 women from across the United States who ranged 
in age from 21 to 69. Smokers had a greater prevalence of non-adherence to Pap testing 
than nonsmokers (Datta et al., 2006). Hewitt and colleagues (2004) analyzed data from 
the 2000 NHIS, which included about 13,700 participants 18 years of age and older. 
Among women ages 25 to 44 years, being a former smoker was associated with greater 
Pap test use (Hewitt et al., 2004). An analysis of the 1998 National Health Interview 
Survey data revealed that current smokers were less likely to report a recent Pap test, 
which remained consistent across ethnicities (Selvin & Brett, 2003).  
Weight. No U.S.-based studies were found that assessed the association between 
body mass index (BMI) and Pap test adherence in HIV-infected women. In the Swiss 
cohort, women who were underweight, which was defined as a BMI of less than 18 
kg/m2, were more likely to have had fewer Pap smears (Keiser et al., 2006. Being obese 
and having a BMI greater than 35 kg/m2 were predictors of fewer Pap smears in women 
participating in the Swiss cohort study (Keiser et al., 2006).  
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More US-based studies have linked obesity to poor adherence to Pap testing in 
uninfected women; however, the data are mixed. Two studies found that obese women 
are less likely to participate in cervical cancer screening (Datta et al., 2006; Ferrante, 
Chen, Crabtree, Wartenberg, 2007). Women with a BMI of greater than 30 kg/m2 were 
less likely than women with a BMI between 20 kg/m2 and 29 kg/m2 to adhere to Pap 
screening (Datta et al., 2006). Data from the 2000 National Health Interview Survey 
revealed that U.S. women ages 40 to 74 years with a BMI greater than 30 kg/m2 were less 
likely to adhere to Pap smears (Ferrante et al., 2007). Two literature reviews using 
articles from 1990 through 2009 suggest that obesity negatively affected Pap screening in 
White women (Aldrich & Hackley, 2010; Cohen et al., 2008). In contrast, one study 
found no association between weight and adherence (Blackwell et al., 2008).  
Education. Poor Pap test adherence was associated with having less than a high 
school education (Del Maso et al., 2010; Keiser et al., 2006; Tello et al., 2010). A cross-
sectional study conducted in Northern Italy between July 2006 and June 2007 included 
1,002 HIV-infected women. The goal of the study was to assess factors associated with 
adherence to cervical cancer screening during a one-year period. Women with less than a 
high school education were less likely to report having a Pap in the year before the 
questionnaire (Del Maso et al., 2010). Another study examined barriers to adherence to 
gynecologic care in 200 women at the Johns Hopkins HIV Clinic via survey. Having less 
than a high school education was associated with not having a Pap smear in the previous 
year (Tello et al., 2010). Among the Swiss cohort study participants, having less 
education, defined as less than completion of mandatory school, was a predictor of fewer 
gynecologic examinations and Pap smears.  
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Having less than a high school education was associated with lower Pap test 
adherence in uninfected women (Bazargan et al., 2004; Coughlin, King, Richards, & 
Ekwueme, 2006; Daley et al., 2011; Datta et al., 2006; Hewitt et al., 2004; Peterson et al., 
2008; Selvin & Brett, 2003), but another study concluded that education had no effect on 
Pap test adherence (Blackwell et al., 2008). Twenty-one regional coordinators, health 
care providers, and administrators in the state of Florida were interviewed about patient 
barriers to cervical cancer screening, and they reported that low levels of education 
prevented women from adhering to cervical cancer screening (Daley et al., 2011). Among 
19,000 women living in the southeastern United States, 30% had less than a high school 
education and 85% had not had a Pap test (Peterson et al., 2008). Having less than a high 
school education was associated with low Pap test adherence in roughly 250,000 women 
who participated in the Behavioral Risk Factor Surveillance System conducted between 
2000 and 2002 (Coughlin et al., 2006). Having less than a high school education was 
strongly associated with poor Pap test adherence in nearly 60,000 women in the Black 
Women’s Health Study (Datta et al., 2006). Pap testing rates were lower in women with 
less than a high school education in about 14,000 women of various ethnic backgrounds 
from across the United States (Hewitt et al., 2004). The association between having a 
lower level of education and poor Pap test compliance was statistically significant among 
230 African American and Latino women living in three urban public housing 
communities in Los Angeles (Bazargan et al., 2004). Women with a bachelor’s degree or 
higher were 2.5 times more likely than women with less than a high school education to 
report a recent Pap test, holding race/ethnicity constant (Selvin & Brett, 2003).  
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Economics. Economic issues, such as a patient’s inability to pay for health 
services due to lack of insurance or lack of financial resources, have been found to 
contribute to patient reluctance to seek preventive care. In a study by Andrasik, Rose, 
Pereira, and Antoni (2008), African American HIV-infected women, between the ages of 
18 and 49 years and living in Miami, who had no history of a Pap test in the 5 years 
before being interviewed, were asked questions to identify barriers to cervical cancer 
screening. Seventy-seven percent of the women reported an annual income of less than 
$10,000 and 80% reported being unemployed. Many of the women reported being 
frustrated with their experiences while seeking medical care without insurance and 
without the ability to pay for medications, services, gas, parking, or bus tickets to get to 
appointment, all of which, consequently, created barriers to cervical cancer screenings 
(Andrasik et al., 2008). A chart review of 200 women receiving care at a health 
department in Florida revealed that women who had not received a Pap test in their first 
year of HIV care were likely not to have had insurance (Logan, Khambaty, D’Souza, & 
Menezes, 2010). One study disagreed with this trend, however. Stein and colleagues 
(2001) used data from the HIV Cost and Service Utilization Study to examine the 
sociodemographic, clinical, and provider factors associated with screening for cervical 
cancer in HIV-infected women. The sample included 49,490 women from across the 
United States. Income and insurance status were not associated with receiving a Pap test 
(Stein et al., 2001). Data for uninfected women were mixed.  
Many individuals cannot afford to pay for medical services, including Pap testing, 
because of lack of insurance and the ability to pay. One article reported that insurance 
had no effect on Pap testing among approximately 3,000 U.S. women participating in the 
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2002-2003 Joint Canada/United States Survey of Health (Blackwell et al., 2008). 
Although the data were mixed, most articles suggested that lack of insurance and inability 
to pay for services decreased the odds of HIV-infected women having had a Pap test per 
currently recommended guidelines (Bazargan et al., 2004; Daley et al., 2011; Hewitt et 
al., 2004; Peterson et al., 2008; Warren, Londono, Wessel, & Warren, 2006).  
Risky behaviors. Former and current drug use was associated with poor Pap test 
adherence among 233 HIV-infected women receiving care at Boston Medical Center 
(Baranoski et al., 2011). When limiting the study to African American women attending 
the Johns Hopkins HIV Clinic, substance abuse was associated with not having a Pap 
smear in the previous year (Tello et al., 2010). In chart reviews of 1,086 women attending 
the Johns Hopkins HIV Clinic, Tello and colleagues (2008) revealed that illegal 
substance use decreased the odds of a woman showing up for HIV-gynecological 
appointments. Two hundred women attending a Florida county health department, who 
reported participating in high risk behaviors such as injection drug use, were less likely to 
have a documented Pap smear, but the association was not statistically significant (Logan 
et al., 2010). Being a current intravenous drug user was associated with fewer Pap smears 
in the Swiss cohort (Keiser et al., 2006). Women participating in a qualitative study in 
Miami reported that more urgent needs, such as substance use, took priority over getting 
screened for cervical cancer (Andrasik et al., 2008).  
One study reported risky behavior as a barrier to cervical cancer screening in 
uninfected women. Regional coordinators, health providers and administers in 10 rural 
counties were interviewed regarding individual barriers to cervical cancer screening; they 
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reported that behaviors such as drug use and having multiple sexual partners were 
barriers (Daley et al., 2011).  
 HIV viral load. HIV viral load is the amount of virus in blood. Women with low 
viral loads are usually more compliant with care guidelines. Women in the Swiss HIV 
Cohort Study with viral loads lower than 400 copies/mL had had fewer Pap smears 
(Keiser et al., 2006). Tello and colleagues (2008) did not find a statistically significant 
association between viral load and Pap smear adherence but Tello and colleagues (2010) 
reported that not having a Pap test in the previous year was associated with viral loads of 
50 copies/mL or greater. A viral load of greater than 10,000 copies/mL was reported to 
be associated with no Pap testing during an 18-month period (Baranoski et al., 2011).  
 CD4+ T lymphocyte count. Having a low (undetectable) CD4+ T lymphocyte 
count or a CD4+ T lymphocyte count lower than 200 copies/mL were associated with no 
Pap or poor Pap test adherence (Baranoski et al., 2011; Del Maso et al., 2010; Oster et al., 
2009; Rahangdale et al., 2010;  Tello et al., 2008). Only one study did not find a 
statistically significant relationship between lower CD4+ T lymphocyte counts and Pap 
test adherence (Keiser et al., 2006).  
Champion’s Health Belief Model Scale and Cervical Cancer 
 Several studies have used Champion’s Health Belief Model (CHBM) scale to 
examine or predict factors associated with cervical cancer screening. This instruments 
measures perceived susceptibility, perceived seriousness, perceived barriers and 
perceived benefits. The research has been conducted in college women including nursing 
students, lesbians, and women over the age of forty. Champion’s Health Belief Model 
scale has been translated and used to assess women in Iran, Thailand, and Korea. The 
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scale has not been used to assess women infected with HIV; therefore, the purposed 
research added to the existing body of knowledge.  
 Perceived susceptibility.  Woman’s perception of their susceptibility to 
cervical cancer varied. Ninety percent of Hispanic women participants felt that they were 
susceptible to cervical cancer but susceptibility was not associated with previously 
having a Pap test (Byrd, Peterson, Chavez & Heckert, 2004). In contrast, 209 Vietnamese 
women living in Texas did not perceive that they were at risk for cervical cancer (Ho, 
Yamal, Atkinson, Basen-Engquist, Tortolero-Luna & Follen, 2005). Seventy-nine percent 
of the Vietnamese women were married which could contributed to their low perceived 
risk of cervical cancer (Ho et al., 2005). A qualitative study involving, low-income 
African American and Hispanic women age fifty and older believed that all women who 
are sexually active are at risk for cervical cancer (Guilfoyle, Franco & Gorin, 2007). 
More than 80% of female students at a New England college believed that they were very 
unlikely to contract a sexually transmitted infection (STI) but only 40% believed that 
they were unlikely or very unlikely to develop cervical cancer (Burak & Meyer, 1997). 
About 70% of 189 Thai women believed they that would not develop cervical cancer or 
were not at risk (Boonpongmanee & Jittanoon, 2007). Only one Thai woman reported 
ever having a STI which could be the result of not being sexually, being educated or 
using condoms more frequently. Mean perceived susceptibility subscale score were 17.4 
for college aged women attending a large Midwestern university which could be the 
result of high condom use, 66.7% of the participants having a Pap test with the past year 
or 77% of the participants not being smokers (Ingledue et al., 2004). Similar results were 
reported among 240 nursing students (Denny-Smith, Bairan & Page, 2006). Twenty-five 
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percent of women age forty to seventy believed that they were at risk for developing 
cervical cancer which may be attributed to more than fifty percent of the participants 
being married (Montgomery, Bloch, Bhattacharya & Montgomery, 2010).  
In several studies, women who received Pap testing or intended to receive a Pap 
test had a greater perception of susceptibility for developing cervical cancer than those 
who had never had one or who had not had a pap test during the previous year (Ingledue, 
Cottrell & Bernard, 2010; Tracy, Lydecker & Ireland, 2010; Ben-Natan & Adir, 2009; 
Burak & Meyer, 1997). Despite higher scores for perceived susceptibility, many of the 
findings were not statistically significant for women who were screened routinely and 
those who were not (Ben-Natan & Adir, 2009; Montgomery, Bloch, Bhattacharya & 
Montgomery, 2009; Boonpongmanee & Jittanoon, 2007; Denny-Smith et al., 2006; Park, 
Chang & Chung, 2005; Burak & Meyer, 1997). In other studies there was no difference 
between groups (Parks et al., 2005; Allahverdipour & Emami, 2008). There was not a 
significant difference between women who had a Pap and women who did not but only 
twenty-two percent of the women reported having had a Pap test (Ben-Natan & Adir, 
2009).  Of the 108 lesbians, only 30.8 percent intended to be tested within the year but 
there was a significant difference between women who intended to be tested and women 
who had no intentions of receiving a Pap test (Ben-Natan & Adir, 2009). The previous 
study was conducted in Israelian women with 94.4% of the women reporting their 
relationship status as single and the article failed to report the perceived susceptibility 
scores (Ben-Natan & Adir, 2009). Among 225 lesbians in the Baltimore metro area, 
women who were not screened routinely had a greater perception of being susceptible to 
cervical cancer (Tracy et al., 2010). In many of the studies reviewed, perceived 
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susceptibility was not a great predictor of Pap testing; contrary, to other studies, 
knowledge and perceived susceptibility and severity were significant predictors of yearly 
Pap test among 428 college women at a large Midwestern university, but perceived 
susceptibility was not a good predictor alone (Ingledue et al., 2010). Boonpongmanee and 
colleague (2007) reported perceived susceptibility as one of three predictor of Pap 
testing. 
Perceived seriousness. Some women seem to understand the seriousness of 
cervical cancer (Byrd et al., 2004; Burak & Meyer, 1997), but in several studies 
differences between groups (Pap vs. no Pap and intenders vs. non-intenders) were not 
significant, if a difference exist (Montgomery et al., 2010; Tracy et al., 2010; Ben-Natan 
& Adir, 2009; Boonpongmanee & Jittanoon, 2007; Denny-Smith et al., 2005; Park et al., 
2005; Burak & Meyer, 2005: Byrd et al., 2004). Perceived seriousness (severity) scores 
were low ranging for 17 to 24 out of a possible 45 (Montgomery et al., 2010; Ho et al., 
2009; Allahverdipour & Emami, 2008; Denny-Smith et al., 2005; Ingledue et al., 2004).  
Only two percent (4/206) Vietnamese women believed that cervical cancer is serious but 
the translations ask that women if they were afraid of cervical cancer which does not 
mean seriousness (Ho et al., 2005). Among college student at a large Midwestern 
university perceived seriousness was negatively correlated with knowledge (Ingledue et 
al., 2004) but in a similar study in college students at a large southeastern university, the 
inverse relationship was not significant. The southeastern study was conducted in nursing 
student who may have more knowledge about HPV and cervical cancer, but most the 
college women did not believe that cervical cancer was serious.  In a study among 
women forty to seventy years of age using the same questionnaire as the previously 
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reported studies, found a positive relationship between knowledge and perceived 
seriousness but the internal consistency was low (α =0.20).   
Contrary to previously reported studies, perceived seriousness differed between 
woman who had had a Pap over the past year, women who had had a Pap but not over the 
past year and women had never had a Pap (Ingledue et al., 2004). Non-routine, lesbian 
Pap screeners had a greater perception that cervical cancer was serious but their scores 
did not differ significantly from routine screeners (Tracy et al., 2010). Perceived 
seriousness scores were higher among the 225 self-identified lesbians than other studies, 
greater than thirty out of a possible forty-five (Tracy et al. 2010). Perceived seriousness 
does not appear to be a good predictor of cervical cancer screening.  
Perceived barriers. Perceived barriers and benefits appear to be significant 
predictive variables related to Pap testing and risk behaviors such as condom use and 
number of sexual partners. It is difficult to separate the two variables, but we explained 
the literature regarding the two variables in separate paragraphs. Women who had a 
history of a previous Pap test perceived fewer barriers than those who did not report a 
history of a previous Pap test (Allahverdipour & Emami, 2008).  Perceived barriers were 
cited as a significant predictor of having had a Pap test (Tracy et al., 2010; 
Allahverdipour & Emami, 2008; Lee et al., 2008; Boonpongmanee & Jittanoon, 2007; Ho 
et al., 2005).   Procedural and cognitive barriers including feelings of embarrassment and 
shame and worrying about results were significantly less in the forty women in the 
experimental group (Park et al., 2005). Similarly, Park and colleagues reported fear of 
pain and embarrassment, partner disapproval and not knowing where to obtain a Pap test 
as factors associated with never having had a Pap test (Byrd et al., 2004). 
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Boonpongmanee and Jittanoon (2007) also reported embarrassment, fear and knowing 
where to obtain a Pap test as perceived barriers; in addition to, forgetting, being too busy 
and the cost of the test. The experimental group received one-one hour session which 
provided information about cervical cancer and Pap smear. Perceived barriers were a 
predictor for Pap testing in a Thailand study of 189 women ages twenty-five to fifty-five 
(Boonpangmanee & Jittanoon 2007).  
Two qualitative studies reported barriers to Pap testing. Korean women in South 
Korea reported the following barriers: cost, lack of insurance, lack of time, language 
difficulties, fatalistic attitudes, embarrassment, lack of knowledge and being 
asymptomatic (Lee, 2000). Seven years later a similar study was conducted in New York 
in older women who reported the same barriers (Guilfoyle et al., 2007). Additionally, the 
researchers reported having a previous negative experience with a provider as a barrier. 
For example: providers not communicating results and having unnecessary exploratory 
procedures (Guilfoyle et al., 2007).   
Perceived benefits. Women who had Pap tests were more likely to have the 
perception that the benefits outweighed the barriers (Tracy et al., 2010; Lee et al., 2008; 
Boonpangmanee & Jittanoon 2007; Ho et al., 2005; Burak & Meyer, 1997). Women who 
participated in an intervention aimed at increasing knowledge about cervical cancer and 
Pap test reported more benefits (Park et al., 2005). Four hundred undergraduate female 
students at a New England state college completed a survey and 104 reported that they 
had no intention of getting a Pap smear while 226 reported that they had not had one in 
the past six months but would be getting a Pap smear during the current year. The women 
who intended to get a Pap smear perceived more benefits than barriers and felt more 
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susceptible to developing HPV (Burak & Meyer, 1997). Likewise in a study among 
Korean women living in California, those who believed they had fewer benefits and more 
barriers had decreased odds of having had a Pap test (Lee, Fogg, Menon, 2008). In a 
study among young Hispanic women perceived benefits were not associated with having 
a pervious Pap test (Byrd et al., 2004). More benefits and fewer barriers were better 
predictors of having had a Pap test (Boonpangmanee & Jittanoon 2007; Burak & Meyer, 
1997).  
Knowledge 
 Two studies with the purpose of assessing knowledge of, perceived susceptibility 
to, perceived seriousness of and risk behaviors regarding HPV and cervical cancer were 
conducted in female college students, specifically nursing students in the first study. Both 
found no significant relationship between HPV/cervical cancer knowledge and perceived 
susceptibility (Denny-Smith, Bairan & Page, 2006; Ingledue, Cottrell & Bernard, 2004) 
but the two studies differed in its findings regarding the relationship between knowledge 
and seriousness. Among 240 bachelor’s degrees seeking nursing students a significant 
positive relationship was not found between HPV/cervical cancer knowledge and 
perceived seriousness (Denny-Smith, Bairan & Page, 2006). Oddly, among 428 
traditional student attending a large Midwestern university, a significant negative 
correlation was found between HPV/cervical cancer knowledge and perceived 
seriousness (Ingledue et al., 2004). The significant finding may be attributed to low levels 
of knowledge regarding HPV/cervical cancer, mean knowledge score 6.8/15 (Ingledue et 
al., 2004). Another study with the same purpose and utilizing the same instrument was 
conducted in women between the ages of forty and seventy found little to no relationship 
30 
 
between knowledge, perceived seriousness and perceived susceptibility (Montgomery, 
Bloch, Bhattacharya & Montgomery, 2010). 
Knowledge was associated with Pap test adherence. Women who were more 
knowledge about cervical cancer were more likely to have had a Pap smear during a 
twelve month period (Ingledue et al., 2004). Women who knew that Pap test could detect 
cervical cancer early were five times more likely to have had a Pap test than women who 
were not knowledgeable (Lee at al., 2008). Three hundred and thirty-three Iranian women 
were surveyed using CHBM scale to assess for associations between HBM variables and 
participation in cervical cancer screenings. Pap test knowledge increased as perceived 
benefits to early detection increased and perceived susceptibility to cervical cancer 
increased (Allahverdipour & Emami, 2010).  
Summary 
 The human papillomavirus (HPV) is a group of viruses that are sexually 
transmitted and if left undetected or untreated can lead to cancer. The most common 
cause of cervical cancer is HPV. Women infected with HIV are at an increased risk of 
acquiring HPV and developing cervical cancer. Cervical cancer screening guidelines for 
HIV-infected women require Pap testing more frequently. Many HIV-infected women do 
not adhere to cervical cancer screening regardless of the current ACOG guidelines. A 
review of literature has uncovered many cited factors that are barriers to cervical cancer 
screening in women and more specifically HIV-infected women. These barriers include 
older age, ethnicity/race, weight, tobacco use, level of education, economics, risky sexual 
behavior, high HIV viral load and low CD4+ T lymphocyte count.  
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 The studies found pertinent information that could be the foundation for future 
interventions domestically and internationally and in various women from lesbians to 
married women to college women involved in risky sexual behavior. The proposed study 
was critical because the population being evaluated consists of women who are at a 
greater risk for developing cervical dysplasia and cervical cancer secondary to being 
immune compromised and having a history of being involved indirectly or directly in 
risky sexual behavior. Further, this study measured perceived self-efficacy to cervical 
cancer screening using CSE scale: therefore, making this aspect of the proposed study 
unique. 
  
32 
 
 
 
 
Chapter Three: Method 
 
 The methods section describes the research design, the study participants, 
sampling procedure, sample size, measures used for data collection, procedure for 
collecting data and method of data analysis. Figure 1 illustrated a conceptual model of the 
concepts evaluated in the study.  
Design 
 The study is an exploratory, cross-sectional, quantitative correlational design. A 
correlational design was selected because the researcher is exploring relationships among 
variables. The dependent or outcome variable is adherence to cervical cancer screening 
using Pap testing. The design allowed the researcher to predict the outcome variable 
using multiple independent variables.  
Population/Setting 
Participants were recruited from the waiting rooms of two health department’s 
HIV ambulatory care center located in central Florida. The clinics were selected because 
they served patients infected with HIV and Acquired Immune deficiency Syndrome 
(AIDS). The clinic serves more than 1,000 patients annually, of whom, about 400 are 
women. The reported cases of HIV from 1983 to June 2011 by race/ethnicity for the rural 
county are as follows: 56% were Black/African American women, 31% were White, 11% 
were Hispanic (all races), one percent was identified as multi-race and less than one 
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percent was identified as American Indian/Native American or Native Hawaiian/Pacific 
Islander. The clinic is staffed with one medical doctor and two advanced registered nurse 
practitioners (ARNP). The specialties of the medical doctor include: internal medicine, 
pediatrics, and infectious disease. The specialties of the ARNPs include: family health, 
adult health and infectious disease.  
Sample 
A convenience sample drawn from the patient population at the study site was 
used. Inclusion criteria were as follows: the participants must be women, 18 years of age 
or older, and patients of the clinic to participate. Women with a history of having had a 
hysterectomy and women who cannot read and comprehend the English language were 
excluded from the study. Each woman received a $15 Walmart gift card as compensation 
for her time. 
  Power analysis was conducted for Pearson’s r using a small (0.2) effect size 
assuming power = .80 and α = .05. The analysis indicated that the sample size needed 
was 192. Also a power analysis was conducted using an effect size of (0.3) assuming 
power = .8 and α = .05 and the sample size needed was 83. For analysis of variance 
(ANOVA) assuming power = .80 and α = .05, the sample size needed for a medium 
effect (0.5) was 64 women in each group for a total of 128 women. A power analysis for 
multiple logistic regression using a tolerance of .60, assuming power = .80 and α = .05 
and a assuming an odds ratio of at least two indicated a sample of size of 276. Although 
the power analysis for multiple regression indicated sample size of 276, the desired 
sample size for the study was n=300. Over sampling by 24 participants was done to 
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account for missing data in the event that a small percentage of the participants elected 
not to answer every question.   
Instruments 
Six scales, one demographic questionnaire, four questions and one chart review 
questionnaire were used in the proposed study. The scales are described in the following 
paragraphs. 
Demographic questionnaire. The demographic questionnaire was developed by 
the researcher. The questionnaire included 20 questions regarding age (not date of birth), 
race/ethnicity, marital status, primary language, education level, CD4+ T lymphocyte 
count, HIV viral load, hysterectomy history, height, weight, cigarette use, substance use, 
Pap test history, number of sexual partners, condom use and year of HIV diagnosis. The 
demographic questionnaire was done in two parts: part one was a medical record review 
completed by the primary investigator and part two was completed by the participant. 
The questions were selected based on the review of related literature.  
Champion’s Health Belief Model scale. Perceived susceptibility, perceived 
seriousness (severity), perceived benefits, and perceived barriers were measured using an 
adapted version of Champion’s Health Belief Model (CHBM) (1984) scale for cervical 
cancer and Pap test. Champion’s Health Belief Model scale consists of four sub-scales. 
The four sub-scales, totaling 28-items, are measured with a 5-point Likert-like scale 
ranging from strongly agree to strongly disagree (Guvenc et al., 2011; Champion, 1998). 
Reported internal consistency for perceived susceptibility, seriousness and barriers is .70 
and above (Guvenc et al., 2011; Medna-Shepherd & Kleier, 2010; Champion, 1984). 
Internal consistency for perceived benefits varied ranging from .62 to .80 (Guvenc et al., 
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2011; Medna-Shepherd & Kleier, 2010; Champion, 1999, Champion, 1984). Test-retest 
reliability coefficients for the perceived benefits, barriers, seriousness and susceptibility 
have ranged from .65 to .88 (Guvenc et al., 2011; Medna-Shepherd & Kleier, 2010; 
Champion, 1999, Champion, 1984). Construct validity for perceived benefits, barriers, 
seriousness and susceptibility was examined by factor analysis and most of the items 
loaded on their perspective factors at .35 and above (Guvenc et al., 2011; Medna-
Shepherd & Kleier, 2010; Champion, 1999, Champion, 1984). 
Champion’s self-efficacy scale. Self-efficacy (confidence) were measured using 
Champion’s Self-Efficacy (CSE) (2005) scale, which consisted of ten questions. The 
scale is measured with a 5-point Likert-like scale ranging from strongly agree to strongly 
disagree (Champion, Skinner & Menon, 2005). The CSE scale has not been widely 
utilized in research. The scale has a Cronbach’s alpha of .87 and a Pearson’s coefficient 
of .52 for test-retest reliability.  
HPV/Cervical cancer knowledge. Human papillomavirus and cervical cancer 
knowledge was measured by fifteen-multiple choice questions. The questionnaire was 
developed by Ingledue and colleagues (2004). The original scale consisted of 40-items 
measuring HPV and cervical cancer knowledge, perception and preventive behaviors. For 
the purposes of this study, the first 15-items measuring HPV and cervical cancer was 
used. Each question has one correct response. The possible range of scores is from zero 
to fifteen and higher scores equate to more knowledge (Denny-Smith et al., 2006; 
Ingledue et al., 2004). Content validity for the knowledge portion of the test was 
determined by a panel consisting of two gynecologists, two professors of health 
education, and a medical professional from the Breast and Cervical Program (Ingledue et 
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al., 2004). Test-retest reliability for knowledge was .90 (Ingledue et al., 2004).  Internal 
consistency for the knowledge scale was not reported.  
Cues to action. Cues to action was evaluated with one question, developed by the 
researcher. The question assessed triggers that encouraged women to get a Pap smear. 
Data Collection 
Data collection began after the study was approved by the Florida Department of 
Health’s Institutional Review Board (IRB) (Appendix A).  Participants were recruited 
from the waiting room of a local health department’s HIV ambulatory care clinic. To 
reduce the risk of identifying the participants, the researcher requested a waiver of 
documentation of consent because the consent form would be the only document 
identifying the patient by name. Each participant was given an informed consent cover 
letter, a survey and an envelope. The informed consent cover letter informed the 
participants that their involvement was voluntary and would not influence the care they 
received (Appendix B). The participant implied consent to the study by completing the 
survey. Each survey was assigned a unique identifier. The unique identifier was written 
on the top of both surveys. The unique identifier allowed the researcher to match the 
participant’s completed survey to the chart review questionnaire. 
 Data collection occurred in two phases. Phase one consisted of a self-administered 
survey completed by the participant (Appendix C). The survey could be completed in 45 
minutes or less. Phase two consisted of a review of the participant's chart by the 
researcher (Appendix D). The chart review was completed while the participant was 
completing the self-administered survey. After completing the questionnaire, the 
participant showed the survey to the researcher who reviewed it for completeness. If the 
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questionnaire was not complete, the participant was given an opportunity to answer any 
incomplete questions. At that time, the researcher gave the participant a $15 Walmart gift 
card as compensation for her time.  The surveys was placed in an envelope and locked in 
a secure office in a locked cabinet. In addition, completed surveys were scanned and 
saved to a password-protected flash drive. The original documents were shredded after 
the documents are scanned. The data will be maintained for 5 years as per DOH IRB 
policy.  
Data Analysis 
The data were analyzed using SPSS statistical software (Version 21). Descriptive 
statistics were used to describe sample characteristics and Pap smear adherence. Means 
and standard deviations were calculated for perceived susceptibility, seriousness, barriers, 
benefits and self-efficacy, in addition to HPV and cervical cancer knowledge. Pearson’s 
correlation coefficients were calculated to assess the relationship within the HBM 
variables and between the demographic. Analysis of variance (ANOVA) was used to 
determine whether mean differences exist for perceived susceptibility, seriousness, 
barriers, benefits and self-efficacy and knowledge between women who report having 
had a Pap test during the past year and women reporting not having had a Pap test during 
the past year. Multiple logistic regression was used to determine whether the perceived 
susceptibility, seriousness, barriers, benefits, self-efficacy and knowledge predict cervical 
cancer screening adherence. Also multiple logistic regression was used to determine 
whether age, race/ethnicity/ marital status, primary language, education level, CD4+ T 
lymphocyte count, HIV viral load, BMI, tobacco use, substance use, history of abnormal 
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Pap test, number of sexual partners, condom use and year of HIV diagnosis are predictors 
of cervical cancer adherence.  
Summary 
The proposed study was an exploratory, cross-sectional, quantitative correlational 
design with the purpose of evaluating HIV-infected women’s knowledge of and 
perceived susceptibility to cervical cancer, and their perceived seriousness of developing 
cervical cancer, as well as assessing their perceived self-efficacy, benefits, and barriers 
and health motivation to cervical cancer screening. In addition, the relationship between 
select demographic factors and cervical cancer screening were evaluated. The women 
were recruited from two specialty care clinics in central Florida. The sample was one of 
convenience with the expectation of having a sample of 300. The following instruments 
were used: CHBM and CSE scales and HPV/cervical cancer knowledge scale by Dr. 
Sandmaire. The validity and reliability of the previously stated instruments were assessed 
in published articles. The participants were given a questionnaire with a consent form. 
The researcher collected the consent form, which contained the patient’s unique 
identifier. The researcher reviewed the questionnaire for completeness and the participant 
placed the questionnaire in an envelope.  After completing the questionnaire, a $15 
Walmart gift card was given. Then, the data was analyzed using SPSS version 21. 
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Chapter Four: Results 
 
The purpose of this study was to evaluate HIV-infected women’s knowledge of 
and perceived susceptibility to cervical cancer, and their perception of the seriousness of 
developing cervical cancer, as well as assessing their perceived self-efficacy, benefits, 
and barriers to cervical cancer screening. In addition, predictors of cervical cancer 
screening in HIV-infected women were evaluated. Chapter four presents the results from 
the pencil and paper survey, which consisted of a participant survey and chart review 
survey. The chapter results are presented in five sections. Section one presents descriptive 
statistics of health-related behaviors, socio-demographic, clinical and subscale variables. 
Section two presents data related to the relationships between Pap test adherence 
(participant reported and chart review), and the following subscales: CHBM, CSE and 
HPV knowledge using ANOVA. In section three, the relationships between the following 
subscale variables: CHBM, CSE and HPV knowledge scales, and select demographic 
variables using ANOVA and Pearson’s correlations are presented. Multiple logistic 
regression results between Pap test adherence (participant reported and chart review) and 
potential predictor variables are presented in section four. Section five presents 
Cronbach’s alpha values to evaluate internal consistency of study instruments. In 
addition, the relationship between sources of last Pap smear reported and the relationship 
between sources of having a history of an abnormal Pap smear. 
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Sample Characteristics 
 The sample consisted of 300 participants, who were recruited from two (one rural 
and the other metropolitan) ambulatory HIV care clinics in Florida. The majority of 
participants were Black (70.3%). Ethnicity was categorized as African American (68%), 
Hispanic-Latina (14%), Caucasian (16.3%), and other (1.7%). The majority of 
participants had at least a high school education (Table 1). 
Table 1. Frequency and Percent of Participants by Sociodemographic Variables. 
Variables Frequency Percent 
Race   
     Black 211 70.3 
     White 89 29.7 
Ethnicity   
     African American 204 68.0 
     White (non-Hispanic) 49 16.3 
     Hispanic/Latina 42 14.0 
     Other 5 1.7 
Education   
     Less than high school 99 33.0 
     High school/trade school 151 50.3 
     College 50 16.7 
Primary Language   
     English 260 86.7 
     Spanish 24 8.0 
     Creole 15 5.0 
     Other 1 0.3 
Marital status   
     Single 163 54.3 
     Divorced 50 16.7 
     Married 48 16.0 
     Significant other 22 7.3 
     Widowed 17 5.7 
Note. n = 300. 
Approximately 50% of the women reported smoking cigarettes. The majority of 
the participants denied a history of current or past substance use. About half of the 
women reported being sexual activity with one partner. The majority of women reported 
using condoms at least 75% of the time (Table 2).  
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Table 2. Frequency and Percent of Participants by Risky Behavior Variables. 
Variables Frequency Percent 
Cigarette usea   
     No 152 50.7 
     Yes 148 49.3 
          Currently 106 71.6 
          Formerly 42 28.4 
Substance usea   
     No 242 80.7 
     Yes 58 19.3 
          Currently 7 11.7 
          Formerly 53 88.3 
Condom usea   
     Never 42 14.0 
     25% 11 3.7 
     50% 13 4.3 
     75% 29 9.7 
     100% 165 55.0 
     I don’t want to answer 40 13.3 
Number of sex partnersa   
     0 96 32.0 
     1 161 53.7 
     2 or more 29 9.7 
     I don’t want to answer 14 4.7 
Sexual activityb   
     Currently active 151 50.3 
     Not active 142 47.3 
     Never 6 2.0 
     Missing 1 0.4 
Note: na = 300, nb = 299. 
All of the women had a diagnosis of HIV, but 48.4% of the women had an AIDS 
diagnosis. A review of  medical charts revealed that less than half of the women were 
diagnosed with depression. The majority of women reported having a Pap smear during 
the past year. However, a review of their medical charts revealed that approximately 56% 
of the women had not had a Pap smear during the past year. Approximately half of the 
women reported not having a history of an abnormal Pap smear, and the medical chart 
revealed similar results (Table 3).  
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Table 3. Frequency and Percent of Participants by Clinical Variables. 
Variables Frequency Percent 
Medical chart review    
     Last Pap smeara   
          < 1 year 131 43.7 
          > 1 year 169 56.3 
     History of abnormal Papc   
         Yes 115 38.3 
         No 169 56.3 
         Missing 16 5.4 
     History of depressiona   
          Yes 129 43.0 
          No 171 57.0 
     Diagnosisa   
          HIV 155 51.7 
          AIDS 145 48.3 
Participant-reported   
     Last Pap smeara   
          < 1 year 224 74.7 
          > 1 year 76 25.3 
     History of abnormal Papb   
          Yes 150 50.2 
          No 149 49.8 
Note: na = 300, nb = 299, nc = 284. 
The participants’ ages ranged from 18 to 70 years old, with a mean age of 45.36 
(SD=11) (Table 4). 35.5 % of the  women were 50 years old, 7.7% of women were 60 
years of age or greater and 10% were 29 years of age or younger. Eighty percent of 
women were recruited from a metropolitan HIV ambulatory clinic and 20% from a rural 
HIV ambulatory clinic.  
Perceived susceptibility measured women’s perceived susceptibility to cervical 
cancer, and perceived susceptibility scores were low. Perceived seriousness included 
seven questions that were used to measure women’s perception of the severity of cervical 
cancer. In general, women perceived that Pap smears were beneficial (M = 15.93). 
Champion’s perceived barriers subscale measured women’s perceived barriers to 
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obtaining a Pap smear, and scores were low (M = 29.26).  HPV/cervical cancer 
knowledge scores were low with a mean of 6.02.  Height and weight were collected for 
each participant, and used to calculate BMI. Ideal BMI range is 18.5 – 24.9, and overall 
the women in this study were overweight (M = 29.25) (Table 4). 
Table 4. Means and Standard Deviation for Subscales, Age and BMI for all Participants. 
Variables Range Mean Standard Deviation 
Age 18 - 70 45.36 11.00 
Perceived Susceptibility 4 - 20 9.59 4.06 
Perceived Benefits 4 - 20 15.93 3.20 
Perceived Seriousness 7 - 35 20.88 6.12 
Perceived Self-efficacy 10 - 50 40.22 6.98 
Perceived Barriers 14 -56 29.16 9.09 
BMI 15 - 55.91 29.25 7.85 
Knowledge 0 - 14 6.02 3.59 
Note: n=300.  
Aim One 
Aim one was to evaluate the relationships between Pap test adherence in women 
infected with HIV and the following variables: a) CHBM scales, b) CSE scale, and c) 
HPV/cervical cancer knowledge scale.  Outcome variables were created from two 
questions on the questionnaire: participant reported last Pap smear was categorized as 
either had a Pap during the past year or no Pap smear, and medical chart review last Pap 
smear was separated into either had a Pap during the past year or no Pap smear.  
Participant reported Pap smear. A one-way ANOVA was used to examine 
differences in subscale variables by participant reported Pap smear. There were 
differences between the following subscale variables (knowledge, susceptibility, 
seriousness and benefits) and participant reported Pap smear, but the differences were not 
statistically significant. Differences in perceived barriers (p >.001; ƞ2 = .016) and self-
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efficacy (p = .029; ƞ2 = .051) by Pap smear adherence were statistically significant. 
Women who reported a Pap smear during the past year had higher perceived self-efficacy 
scores and lower perceived barrier scores than women who reported having a Pap smear 
greater than one year ago (Table 5).  
Table 5. Differences in Subscale Scores by Participant Reported Pap Smear.  
 Pap M SD F df p ƞ2 
Knowledge 
 
<1yeara 5.89 3.74  
1.11 
 
(1,298) 
 
.293 
 
.004 >1yearb 
 
6.39 3.08 
Susceptibility <1yeara 9.65 4.23  
0.26 
 
(1,298) 
 
.611 
 
.001 >1yearb 
 
9.38 3.51 
Seriousness <1yeara 20.63 6.37  
1.40 
 
(1,298) 
 
.239 
 
.005 >1yearb 
 
21.59 5.28 
Benefits <1yeara 16.05 3.23  
1.40 
 
(1,298) 
 
.239 
 
.005 >1yearb 
 
15.55 3.07 
Barriers <1yeara 27.96 9.01  
15.95 
 
(1,298) 
 
.000 
 
.051 >1yearb 
 
32.67 8.46 
Self-efficacy <1yeara 40.73 7.32  
4.83 
 
(1,298) 
 
.029 
 
.016 >1yearb 38.71 5.60 
Note. na = 224, nb = 76. 
Medical chart documented Pap smear. ANOVA (one-way) was used to 
determine differences in subscale variables by medical chart documented Pap smear. The 
analysis revealed that differences in subscale variables by medical chart documented Pap 
smear were small. The relationships between medical chart-documented last Pap smear 
and the subscale variables were not statistically significant (Table 6). 
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Table 6. Differences in Subscale Scores by Medical Chart Reported Pap Smear.  
 Pap M SD F df p ƞ2 
Knowledge 
 
<1yeara 6.11 3.60  
0.16 
 
(1,298) 
 
.689 
 
.001 >1yearb 
 
5.95 3.59 
Susceptibility <1yeara 9.66 4.28  
0.08 
 
(1,298) 
 
.772 
 
.000 >1yearb 
 
9.53 3.89 
Seriousness <1yeara 20.95 6.28  
0.04 
 
(1,298) 
 
.847 
 
.000 >1yearb 
 
20.82 6.02 
Benefits <1yeara 15.79 3.54  
0.40 
 
(1,298) 
 
.527 
 
.001 >1yearb 
 
16.03 2.91 
Barriers <1yeara 29.70 9.22  
1.404 
 
(1,298) 
 
.237 
 
.005 >1yearb 
 
28.45 8.93 
Self-efficacy <1yeara 40.33 7.86  
0.06 
 
(1,298) 
 
.801 
 
.000 >1yearb 40.13 6.23 
Note. an= 131, bn = 169, Total n = 300. 
Aim Two 
Aim two was to evaluate relationships among the subscales (CHBM, CSE, and 
knowledge scales) and select demographic variables in HIV-infected women. Pearson’s 
correlation was used to evaluate the relationship between continuous variables. ANOVA 
was used to assess the relationship between a continuous and a categorical variable.  
 Sociodemographic. The associations between the subscale variables and the 
following sociodemographic variables are presented: race, education, marital status, and 
language. No statistically significant relationships were revealed between the subscale 
variables (CHBM, CSE, and HPV knowledge) and marital status (Table 7). Statistically 
significant relationships were found between subscale variables and the following 
variables: race, education and language.  
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Table 7. Differences in Subscale Scores by Marital Status. 
 Marital 
Status 
M SD F df p ƞ2 
Knowledge 
 
Singlea 5.98 3.47 2.02 (4, 295) .09 .03 
Significant 
otherb 
7.68 3.06 
Marriedc 6.08 4.13 
Divorcedd 5.92 3.54 
Widowede 4.47 3.47 
        
Susceptibility Singlea 9.39 4.03 0.70 (4, 295) .59 .01 
Significant 
otherb 
9.50 4.48 
Marriedc 10.46 4.30 
Divorcedd 9.58 3.48 
Widowede 9.12 4.81 
        
Seriousness Singlea 20.63 6.22 0.86 (4, 295) .49 .01 
Significant 
otherb 
19.82 4.92 
Marriedc 21.96 5.48 
Divorcedd 21.48 6.17 
Widowede 19.77 7.98 
        
Benefits Singlea 15.83 3.46 0.97 (4, 295) .42 .01 
Significant 
otherb 
16.68 2.64 
Marriedc 16.25 2.94 
Divorcedd 15.96 2.79 
Widowede 14.82 2.94 
        
Barriers Singlea 30.00 9.78 1.33 (4, 295) .26 .02 
Significant 
otherb 
29.77 7.57 
Marriedc 28.88 8.01 
Divorcedd 26.70 8.37 
Widowede 28.35 8.51 
        
Self-efficacy Singlea 39.50 7.11 1.09 (4, 295) .36 .02 
Significant 
otherb 
40.36 5.31 
Marriedc 41.58 7.55 
Divorcedd 41.04 6.13 
Widowede 40.71 8.07 
 Note. na = 163, nb = 22, nc = 48, nd = 50, ne = 17, Total n = 300.  
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Race and language. Using ANOVA, statistically significant relationships were 
found between perceived susceptibility and race, and perceived self-efficacy and primary 
language spoken. White women perceived themselves to be more susceptible than black 
women to cervical cancer (p <.001) (Table 8). Using Tukey’s HSD (honestly significant 
difference) post hoc test, pairwise differences were revealed. Women who spoke English 
had higher self-efficacy scores than women who spoke Spanish (p = .035) (Table 9).  
Table 8. Differences in Subscale Scores by Race. 
 Race M SD F df p ƞ2 
Knowledge 
 
Blacka  5.88 3.58 1.11 (1, 298) .29 .00 
Whiteb 6.36 3.61 
        
Susceptibility Blacka  8.98 3.94 16.94 (1, 298) <.001 .05 
Whiteb 11.03 3.98 
        
Seriousness Blacka  20.76 6.48 0.27 (1, 298) .60 .00 
Whiteb 21.16 5.22 
        
Benefits Blacka  16.12 3.28 2.70 (1, 298) .10 .01 
Whiteb 15.46 3.00 
        
Barriers Blacka  28.64 9.32 2.35 (1, 298) .13 .01 
Whiteb 30.39 8.47 
        
Self-efficacy Blacka  40.44 7.22 0.68 (1, 298) .41 .00 
Whiteb 39.71 6.38 
Note. na = 211, nb = 89. Total n = 300.  
Education. Using ANOVA, statistically significant differences exist in 
knowledge, and perceived benefits, barriers and self-efficacy by education. Using 
Tukey’s HSD post hoc test, women with less than a high school education had lower 
perceived self-efficacy scores than women with a high school diploma (p = .019), and 
women with a college education (p = .002). Women with less than a high school 
education perceived more barriers than women with a college education (p =.014). 
Women with less than a high school education perceived fewer benefits to Pap testing 
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than women with a high school diploma (p < .001), and women with a college education 
(p = .001). Women with a college education had higher knowledge scores than women 
with less than a high school education (p <.001) and women with a high school education 
(p =.012) (Table 10). 
Table 9. Differences in Subscale Scores by Primary Language Spoken.  
 Language M SD F df p ƞ2 
Knowledge 
 
Englisha 6.10 3.60 0.53 (2, 296) .59 .00 
Creoleb 5.80 3.65 
Spanishc 5.33 3.60 
        
Susceptibility Englisha 9.42 4.06 2.58 (2, 296) .08 .02 
Creoleb 9.40 4.07 
Spanishc 11.38 3.85 
        
Seriousness Englisha 20.87 6.20 0.00 (2, 296) .99 .00 
Creoleb 20.67 5.58 
Spanishc 20.92 5.90 
        
Benefits Englisha 16.00 3.02 0.83 (2, 296) .44 .01 
Creoleb 15.20 5.05 
Spanishc 15.38 3.65 
        
Barriers Englisha 28.65 8.75 2.23 (2, 296) .06 .02 
Creoleb 31.47 11.20 
Spanishc 32.88 10.70 
        
Self-efficacy Englisha 40.67 6.57 3.90 (2, 296) .02 .03 
Creoleb 38.07 10.35 
Spanishc 37.00 7.92 
Note. na = 260, nb = 15, nc = 24, Total n = 299.  
Age. Bivariate correlations were computed to determine if an association exists 
between the subscale variables and age. A statistically significant weak, negative 
correlation exists between HPV knowledge and age; therefore, as age increases 
knowledge decreases (r = -.292, p < .001). Statistically significant relationships were 
revealed between perceived susceptibility and age (r = -.140, p = .015) and perceived 
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self-efficacy and age (r = -.155, p = .007). As age increases perceived susceptibility and 
self-efficacy decreases (Table 21). 
Table 10. Differences in Subscale Scores by Education.  
 Education M SD F df p ƞ2 
Knowledge 
 
< High schoola  5.22 3.26 8.02 (2, 297) <.001 .05 
High schoolb 6.01 3.50 
Collegec 7.66 3.98 
        
Susceptibility < High schoola  9.99 4.08 0.74 (2, 297) .48 .01 
High schoolb 9.36 4.02 
Collegec 9.46 4.14 
        
Seriousness < High schoola  21.57 6.36 1.01 (2, 297) .36 .01 
High schoolb 20.64 6.10 
Collegec 20.24 5.68 
        
Benefits < High schoola  14.71 3.58 11.68 (2, 297) <.001 .07 
High schoolb 16.46 2.89 
Collegec 16.74 2.57 
        
Barriers < High schoola  30.86 9.80 4.09 (2, 297) .02 .03 
High schoolb 28.94 8.70 
Collegec 26.44 8.24 
        
Self-efficacy < High schoola  38.32 7.42 6.85 (2, 297) <.001 .04 
High schoolb 40.73 6.36 
Collegec 42.44 7.08 
Note. na = 99, nb = 151, nc = 50, Total n = 300.  
Risky behavior. For the purpose of this study risky behaviors consist of the 
following variables: cigarette use, substance use, condom use, number of sexual partners, 
and sexual experience or activity. This section presents data about statistically significant 
relationships between the subscale variables and the risky behavior variables. No 
statistically significant relationship was revealed between the subscales variables 
(CHBM, CSE, and HPV knowledge) and substance use (Table 11). 
Cigarette use. The relationship between perceived susceptibility and cigarette use 
was statistically significant. Although not statistically significant, women who reported a 
history of cigarette use felt that cervical cancer was more serious, and they were more 
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knowledgeable about cervical cancer and HPV. The women were less confident in 
requesting a Pap smear, and they felt that there were more benefits and fewer barriers to 
screening than women without a history of cigarette use (Table 12). 
Table 11. Differences in Subscale Scores by Substance Use. 
 Substance 
use 
M SD F df p ƞ2 
Knowledge 
 
Yesa 6.36 3.06 0.64 (1, 298) .43 .00 
Nob 
 
5.94 3.71 
Susceptibility Yesa 10.26 3.89 1.98 (1, 298) .16 .01 
Nob 
 
9.43 4.09 
Seriousness Yesa 21.62 4.83 1.06 (1, 298) .30 .00 
Nob 
 
20.70 6.39 
Benefits Yesa 15.78 2.33 0.16 (1, 298) .69 .00 
Nob 
 
15.96 3.37 
Barriers Yesa 30.36 9.29 1.26 (1, 298) .26 .00 
Nob 
 
28.87 9.05 
Self-efficacy Yesa 38.69 5.95 3.49 (1, 298) .06 .01 
Nob 40.59 7.16 
Note. na = 242, nb = 58, Total  n = 300. 
Table 12. Differences in Subscale Scores by Cigarette Use. 
 Cigarette 
use 
M SD F df p ƞ2 
Knowledge 
 
Yesa 6.11 3.59 0.19 (1, 298) .66 .00 
Nob 
 
5.93 3.79 
Susceptibility Yesa 10.12 4.25 4.88 (1, 298) .03 .02 
Nob 
 
9.08 3.81 
Seriousness Yesa 21.27 5.97 1.21 (1, 298) .27 .00 
Nob 
 
20.49 6.27 
Benefits Yesa 15.92 2.96 0.00 (1, 298) .97 .00 
Nob 
 
15.93 3.42 
Barriers Yesa 29.22 8.65 0.01 (1, 298) .91 .00 
Nob 
 
29.10 9.54 
Self-efficacy Yesa 39.94 6.67 0.47 (1, 298) .49 .00 
Nob 40.49 7.28 
Note. na = 148, nb = 152, Total n = 300. 
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Condom use. A statistically significant difference in perceived barriers and HPV 
knowledge existed across levels of condom use (p = .035, ƞ2 = .04; p =.046, ƞ2 = .038, 
respectively). No statistically significant pairwise differences were revealed for perceived 
barriers using post hoc testing. Tukey’s HSD post hoc test revealed a statistically 
significant relationship in HPV knowledge between women who reports using condoms 
75% of the times in comparison to women who did not want to report their condom usage 
(p =.027). It should be noted that women who reported using condoms 75% of the time 
had the highest mean knowledge scores (Table 13). 
Number of sex partners. A statistically significant differences were found 
between perceived self-efficacy and HPV knowledge by of number of sexual partners (p 
=.047, ƞ2= .027; p =.027, ƞ2= .030). Post hoc testing for perceived self-efficacy did not 
reveal any statistically significant pairwise differences. Tukey’s post hoc test revealed 
that women who reported not having any sexual partners during the past 12 months had 
lower knowledge scores than women who reported having two or more partners during 
the past year (Table 14). 
 Sexual experience. Statistically significant relationships exist between sexual 
experience and specific subscale variables (perceived self-efficacy and HPV knowledge). 
Using Tukey’s HSD post hoc test, women who reported no sexual activity during the past 
12 months had higher perceived self-efficacy scores than women who reported having 
sex during the past 12 months (p <.001). Women who reported having sex during the past 
12 months had higher self-efficacy scores than women who reported never having sexual 
intercourse (p <.001). Women who reported no sexual activity during the past 12 months 
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had higher knowledge scores than women who reported never having sexual intercourse 
(p = .032) (Table 15). 
Table 13. Differences in Subscale Scores by Condom Use.  
 Condom use M SD F df p ƞ2 
Knowledge 
 
Nevera 5.90 3.68 2.29 (5, 294) .046 .038 
25%b 6.00 3.32 
50%c 4.77 2.62 
75%d 7.52 3.68 
100%e 6.18 3.51 
IDWTAf 4.85 3.81 
        
Susceptibility Nevera 9.45 3.94 0.94 (5, 294) .454 .016 
25%b 8.82 3.34 
50%c 11.61 3.36 
75%d 10.21 3.65 
100%e 9.48 4.13 
IDWTAf 9.28 4.51 
        
Seriousness Nevera 19.90 6.99 0.73 (5, 294) .596 .012 
25%b 20.18 4.47 
50%c 23.23 6.00 
75%d 21.72 4.98 
100%e 20.87 6.00 
IDWTAf 20.73 6.88 
        
Benefits Nevera 15.67 3.36 0.49 (5, 294) .786 .008 
25%b 16.45 2.62 
50%c 15.31 3.22 
75%d 15.41 3.41 
100%e 16.01 3.23 
IDWTAf 16.30 2.95 
        
Barriers Nevera 30.57 8.61 2.44 (5, 294) .035 .040 
25%b 29.45 7.94 
50%c 34.62 8.71 
75%d 31.86 10.57 
100%e 27.81 8.56 
IDWTAf 29.40 10.17 
        
Self-efficacy Nevera 39.74 6.45 1.48 (5, 294) .198 .024 
25%b 36.73 10.55 
50%c 39.08 6.06 
75%d 39.59 6.66 
100%e 41.08 6.63 
IDWTAf 38.98 7.98 
Notes. na = 42, nb = 11, nc = 13, nd = 29, ne = 165, nf = 40, Total n = 300, IDWTA = I don’t want to answer 
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Table 14. Differences in Subscale Scores by Number of Sexual Partners. 
 Number of 
Sex 
partners 
M SD F df p ƞ2 
Knowledge 
 
Zeroa 5.39 3.59 3.10 (3, 296) .027 .030 
Oneb 6.23 3.58 
Twoc 7.45 3.24 
IDWTAd 
 
5.07 3.60 
Susceptibility Zeroa 9.44 3.95 2.20 (3, 296) .089 .022 
Oneb 10.02 4.21 
Twoc 8.52 3.50 
IDWTAd 
 
7.86 3.55 
Seriousness Zeroa 20.40 6.89 0.662 (3, 296) .576 .007 
Oneb 21.32 5.77 
Twoc 20.59 5.35 
IDWTAd 
 
19.71 6.22 
Benefits Zeroa 15.64 3.70 1.01 (3, 296) .390 .010 
Oneb 16.22 3.01 
Twoc 15.59 2.73 
IDWTAd 
 
15.29 2.27 
Barriers Zeroa 30.26 10.0
0 
2.00 (3, 296) .114 .020 
Oneb 28.37 8.46 
Twoc 27.93 9.01 
IDWTAd 
 
33.21 8.87 
Self-efficacy Zeroa 38.76 7.50 2.69 (3, 296) .047 .027 
Oneb 40.77 6.83 
Twoc 42.31 5.69 
IDWTAd 39.57 5.94 
Note. na = 96, nb = 161, nc = 29, nd = 14, Total n = 300, IDWTA = I don’t want to answer. 
Clinical variables. For the purpose of this study clinical variables consist of BMI, 
CD4+ T lymphocyte count, HIV viral load, encouragement, depression, and history of 
abnormal Pap smear (participants-reported and medical chart documented). This section 
presents data about relationships between subscale variables and clinical variables. The 
relationship between depression and the subscale variables was not 
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Table 15. Differences in Subscale Scores by Sexual Experience. 
 Sexual 
Activity 
Mean SD F df p ƞ2 
Knowledge 
 
Currently 
activea 
6.56 3.63 5.04 (2, 296) .007 .033 
Not activeb 5.63 3.47 
Neverc 
 
2.83 2.32 
Susceptibility Currently 
activea 
9.78 4.09 0.31 (2, 296) .735 .002 
Not activeb 9.41 4.04 
Neverc 
 
9.67 4.27 
Seriousness Currently 
activea 
21.09 5.58 0.17 (2, 296) .092 .001 
Not activeb 20.68 6.56 
Neverc 
 
20.67 9.56 
Benefits Currently 
activea 
16.14 2.86 2.41 (2, 296) .092 .016 
Not activeb 15.82 3.47 
Neverc 
 
13.33 4.08 
Barriers Currently 
activea 
28.41 8.38 2.14 (2, 296) .119 .014 
Not activeb 29.69 9.54 
Neverc 
 
35.33 14.25 
Self-efficacy Currently 
activea 
40.99 6.50 11.19 (2, 296) <.01 .070 
Not activeb 39.93 6.75 
Neverc 27.83 12.43 
Note: na = 151, nb = 142, nc = 6, Total n = 300. 
statistically significant (Table 16). The relationship between CD4+ T-lymphocyte and the 
subscale variables was not statistically significant (Table 21). 
HIV viral load. Women with low viremia (VL <500) perceived more benefits to 
cervical cancer screening than women with high viremia (p=.032, ƞ2 = .015). However, 
ANOVA is not robust against unequal group size when the assumption of homogeneity 
has been violated. Welch’s adjust F ratio was utilized, and the difference between HIV  
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Table 16. Differences in Subscale Scores by Medical Chart Documented History of 
Depression. 
 Depression Mean SD F df p ƞ2 
Knowledge 
 
Yesa 6.08 3.41 0.05 (1, 298) .821 .000 
Nob 5.98 3.72 
        
Susceptibility Yesa 9.74 4.09 0.34 (1, 298) .560 .000 
Nob 9.47 4.04 
        
Seriousness Yesa 21.53 5.92 2.63 (1, 298) .106 .001 
Nob 20.38 6.25 
        
Benefits Yesa 15.57 3.13 2.90 (1, 298) .090 .015 
Nob 16.20 3.23 
        
Barriers Yesa 29.85 9.29 1.30 (1, 298) .256 .005 
Nob 28.64 8.94 
        
Self-efficacy Yesa 39.38 6.38 3.31 (1, 298) .070 .014 
Nob 40.85 7.35 
Note: na = 129, nb = 171, Total n = 300. 
viral load and perceived benefits is not statistically significant, Welch’s F(1, 74.84) = 
3.46, p = .067. Women with low viremia had higher perceived self-efficacy scores than 
women with high viremia (p =.042, ƞ2 = .014). Differences between HIV viral load and 
the following subscale variables: knowledge, susceptibility, seriousness, and barriers 
were not statistically significant (p = .554, p = .211, p = .720, respectively) (Table 17).   
Encouragement. Women who reported being encouraged by providers to get a 
Pap smear had higher HPV knowledge scores than women who reported that they were 
not encouraged. Perceived self-efficacy and benefit scores were higher for women who 
reported being encouraged than for women who reported that they were not encouraged 
by providers. The differences were statistically significant, but ANOVA is not robust 
when the assumption of homogeneity is violated in the presents of unequal group size, so 
Welch’s F ration was calculated. Welch’s adjusted F ratio was obtained for perceived 
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benefits and self-efficacy, [Welch’s F(1, 41.89) = 10.47, p = .002; Welch’s F(1, 40.00) = 
12.78, p = .001, respectively] (Table 18) 
Table 17. Differences in Subscale Scores by HIV Viral Load. 
 HIV Viral load Mean SD F df p ƞ2 
Knowledge 
 
Low viremiaa 6.04 3.56 0.02 (1, 298) .892 .000 
High viremiab 5.97 3.77 
        
Susceptibility Low viremiaa 9.55 4.13 0.13 (1, 298) .720 .000 
High viremiab 9.76 3.76 
        
Seriousness Low viremiaa 20.98 6.08 0.35 (1, 298) .554 .001 
High viremiab 20.45 6.33 
        
Benefits Low viremiaa 16.12 3.01 4.63 (1, 298) .032 .015 
High viremiab 15.12 3.82 
        
Barriers Low viremiaa 28.83 9.00 1.57 (1, 298) .211 .005 
High viremiab 30.50 9.47 
        
Self-efficacy Low viremiaa 40.62 6.54 4.15 (1, 298) .042 .014 
High viremiab 38.55 8.42 
Note: na = 242, nb = 58, Total n = 300. Barriers: Welch’s F(1, 74.84) = 3.46, p = .067. 
Table 18. Differences in Subscale Scores by Encouragement by Providers. 
 Encouragement M SD F df p ƞ2 
Knowledge 
 
Yesa 6.43 3.46  
15.56 
 
(1, 219) 
 
<.01 
 
.051 Nob 4.03 3.51 
        
Susceptibility Yesa 9.67 4.00  
0.01 
 
(1, 291) 
 
.914 
 
.000 Nob 9.60 4.52 
        
Seriousness Yesa 21.14 6.00  
1.37 
 
(1, 291) 
 
.242 
 
.005 Nob 19.90 6.48 
        
Benefits Yesa 16.17 2.97  
16.37 
 
(1, 291) 
 
<.01 
 
.053 Nob 13.95 4.02 
        
Barriers Yesa 28.95 8.93  
1.62 
 
(1, 291) 
 
.204 
 
.006 Nob 31.00 10.50 
        
Self-efficacy Yesa 40.95 6.12  
26.02 
 
(1, 291) 
 
<.01 
 
.082 Nob 34.92 10.00 
Note. an= 256, bn = 37, Total n = 293. Benefits: Welch’s F(1, 41.89) = 10.47, p = .002. Self-
efficacy: Welch’s F(1, 40.00) = 12.78, p = .001. 
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Participant-reported history of abnormal Pap. Women who reported having a 
history of an abnormal Pap smear perceived themselves to be more susceptible to cervical 
cancer, and they perceived cervical cancer to be more serious than women without a 
history of having an abnormal Pap smear. Women who reported having a history of an 
abnormal Pap smear perceived more benefits and fewer barriers to Pap smears than 
women without a history of having an abnormal Pap smear.  Women who reported 
having a history of an abnormal Pap smear had higher perceived self-efficacy and 
knowledge scores than women who denied having a history of an abnormal Pap smear 
(Table 19).  
Table 19. Differences in Subscales Scores by Participant Reported History of Abnormal 
Pap Smear.  
 Abnormal Pap M SD F df p ƞ2 
Knowledge 
 
Yesa 6.68 3.63 9.88 (1, 297) .002 .032 
Nob 5.40 3.43 
        
Susceptibility Yesa 10.58 4.15 18.85 (1, 297) <.01 .060 
Nob 8.60 3.74 
        
Seriousness Yesa 21.60 5.70 4.12 (1, 297) .043 .014 
Nob 20.17 6.48 
        
Benefits Yesa 16.39 2.80 6.72 (1, 297) .010 .022 
Nob 15.44 3.50 
        
Barriers Yesa 27.62 8.16 8.47 (1, 297) .004 .028 
Nob 30.64 9.74 
        
Self-efficacy Yesa 41.75 6.19 15.03 (1, 297) <.01 .048 
Nob 38.69 7.42 
Note. an= 150, bn = 149, Total n = 299. 
Medical chart documented history of abnormal Pap. Medical records were 
reviewed for history of an abnormal Pap smear. Participants whose charts indicated a 
history of an abnormal Pap smear had higher perceived susceptibility than women whose 
charts did not reflect a history of an abnormal Pap smear, differences were statistically 
significant (p = .008)  (Table 20). 
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Table 20. Differences in Subscale Scores by Medical Chart Document History of 
Abnormal Pap smear.  
 Abnormal Pap M SD F df p ƞ2 
Knowledge 
 
Yesa 6.31 3.88 1.62 (1, 282) .204 .006 
Nob 
 
5.76 3.42 
Susceptibility Yesa 10.31 4.26 7.15 (1, 282) .008 .025 
Nob 
 
9.00 3.92 
Seriousness Yesa 21.43 5.93 1.41 (1, 282) .236 .005 
Nob 
 
20.54 6.38 
Benefits Yesa 16.30 2.81 2.15 (1, 282) .144 .008 
Nob 
 
15.72 3.50 
Barriers Yesa 28.62 8.52 0.50 (1,282) .479 .002 
Nob 
 
29.40 9.59 
Self-efficacy Yesa 40.91 7.37 1.91 (1, 282) .167 .007 
Nob 39.72 6.94 
Note: na = 115, nb = 169, missing = 16, Total n = 284. 
BMI. Bivariate correlations were used to determine relationships between BMI 
and the subscale variables. A statistically significant but weak correlation between BMI 
and perceived benefits exists (r = .127, p = .027); therefore, women with a higher BMI 
perceived more benefits. A weak but statistically significant correlation between BMI and 
perceived barriers exists (r = -.118, p = .041), so women who perceive more barriers had 
a lower BMI (Table 21). 
Aim Three 
 Logistic regression was used to assess the ability of the subscale variables 
(CHBM, CSE, and HPV knowledge) and select demographic factors to predict Pap 
testing among women infected with HIV. The outcome variables were participant-
reported Pap smear and medical chart documented Pap smear. Predictors were selected 
from existing literature.  
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Table 21. Pearson’s Correlations for Age, CD4 Count, and Subscale Variables. 
Variables 1 2 3 4 5 6 7 8 9 
Age (1)  1                  
CD4 Count (2)  .155** 1                
Susceptibility (3)  -.140* -.009 1              
Seriousness (4)  -.036 .006 .368** 1            
Benefits (5)  -.002 .035 -.054 .130* 1          
Self-efficacy (6)  -.155** .057 -.039 .005 .534** 1        
Barriers (7)  .038 -.094 .284** .290** -.191** -.455** 1      
Knowledge (8)  -.292** -.036 .094 .076 .157** .297** -.176** 1    
BMI (9)  -.042 .265** -.064 -.013 .127* .098 -.118* .040 1  
Note. n = 300. p = < 0.01**, p < 0.05*. 
For participant-reported last Pap smear, all variables were entered into the initial 
equation and perceived barriers was significant, p = .006, OR = .944. A backward 
stepwise approach was taken in eliminating potential predictor variables that were not 
significant.  The following predictors were retained in the analysis: perceived 
susceptibility, perceived barriers, age, CD4+ T lymphocyte count, family history and 
HPV knowledge The results revealed that last CD4+ T lymphocyte count and perceived 
barriers and susceptibility were statistically significant predictors of participant-reported 
last Pap smear (p = .046, p <.001, and p = .004, respectively). Perceived barriers and last 
CD4+ Tlymphocyte count are statistically significant predictors when they are the only 
two variables in the equations, p = .000, OR = 0.946, 95% CI [0.918 – 0.975]; p = .002, 
OR = 1.002, 95% CI [1.001 – 1.002] (Table 22). 
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Table 22. Multiple Logistic Regression of Participant Reported Pap Smear. 
Model β Error Sig. O.R 95% C.I.for O.R. 
Lower Upper 
Susceptibility 
 
.081 .039 .041 1.084 1.003 1.171 
Barriers 
 
-.072 .017 <.001 .930 .899 .963 
Age 
 
.005 .014 .713 1.005 .979 1.032 
CD4 Count 
 
.001 .000 .004 1.001 1.000 1.002 
Family history 
 
.326 .372 .381 1.386 .668 2.876 
Knowledge 
 
-.052 .052 .320 .950 .858 1.052 
Constant 1.692 1.032 .101 5.431   
Note. n = 300, Family history = participant knowing that family history of cervical cancer 
is a risk factor. Model (likelihood ratio) χ2 = 32.15, p <.01. Nagelkerke R2 = .15. 
 
For medical chart documented last Pap smear, all variables were entered into the 
initial equation and no predictors were revealed. Using the same predictors used to 
predict participant reported Pap smear, the following predictors: perceived susceptibility, 
perceived barriers, age, CD4+ T lymphocyte, family history and HPV knowledge were 
used in the analysis. CD4+ T lymphocyte was a statistically significant predictor of 
medical chart-reported last Pap smears (p = .038), but the full model was not statistically 
different from the null model, a model without predictors (p = .392). Therefore there are 
no predictors for medical chart documented Pap smear (Table 23).  
Cronbach’s Alpha 
 Cronbach’s alpha was calculated for the following subscales: perceived 
susceptibility, benefits, barriers, seriousness and self-efficacy. Perceived susceptibility 
and self-efficacy scales had excellent internal consistency (α > .90). The internal 
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consistency for perceived seriousness, perceived barriers and the knowledge scales was 
good. The perceived benefits scale had a Cronbach’s alpha that is interpreted as 
acceptable (Table 24). 
Table 23.  Multiple Logistic Regression of Medical Chart Documented Pap Smear. 
Model β Error Sig. O.R 95% C.I. for O.R. 
Lower Upper 
Susceptibility 
 .017 .031 .575 1.018 .958 1.081 
Barriers 
 -.015 .014 .293 .985 .959 1.013 
Age 
 -.001 .012 .934 .999 .977 1.022 
CD4 Count 
 .001 .000 .038 1.001 1.000 1.002 
Family history 
 -.029 .303 .923 .971 .536 1.758 
Knowledge 
 .004 .043 .928 1.004 .923 1.092 
Constant -.439 .875 .616 .645   
Note. n = 300, Family history = participant knowing that family history of cervical cancer 
is a risk factor. Model (likelihood ratio) χ2 = 6.29, p = .392. Nagelkerke R2 = .28.  
 
Table 24. Reliability of Subscales. 
Subscales Number of items Cronbach’s Alpha Interpretation 
Perceived 
Susceptibility 
 
4 .92 Excellent 
Perceived 
Seriousness 
 
7 .85 Good 
Perceived Benefits 
 
4 .72 Acceptable 
Perceived Barriers 
 
14 .89 Good 
Perceived Self-
efficacy 
10 .92 Excellent 
  KR-20  
HPV Knowledge 15 .81 Good 
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Pap Smear by Source 
 The outcome variable for the current study was Pap smear adherence, but there 
were two possible sources for last Pap smear, participant-reported and medical chart 
documented. The number of women who had not received a Pap smear during the past 
year nearly doubled when the source changed from participant to medical chart (Table 4). 
McNemar test (S) was performed to assess the relationship between medical chart 
documented last Pap smear and participant-reported last Pap smear because the two 
variables are correlated. The relationship was statistically significant, S (1, N= 300) = 
74.9, p <.001. Women who reported having a Pap smear during the past year were more 
likely to have a Pap smear documented in their medical chart. Women who reported 
having a Pap smear greater than 1 year ago were more likely to have a Pap smear 
documented in their chart greater than 1 past year ago (Table 25). 
Table 25. Crosstabs Table of Pap Smear by Source  
Pap Smear S ϕ 
 Participant reported 
Medical Chart Yes No 
Yes 
 
121 
 
10 
 
74.9** .36** 
No 
 
103 
 
66 
 
Note. n = 300. ** = p < .001. 
 
Abnormal Pap Smear by Source 
 Information regarding history of having an abnormal Pap smear was obtained 
from the participant and the medical chart. McNemar test (S) was performed to assess the 
relationship between medical chart documented and participant-reported history of 
having an abnormal Pap smear because the two variables are correlated. The majority of 
women who reported not having a history of an abnormal Pap smear were the same 
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women who did not have a documented history of an abnormal Pap smear. 
Approximately 28% of the women’s response did not match their medical chart (Table 
26). 
Table 26. Crosstabs Table of History of an Abnormal Pap Smear by Source  
History of Abnormal Pap Smear S ϕ 
 Participant reported 
Medical Chart Yes No 
Yes 
 
87 
 
28 
 
7.62* .43** 
No 
 
54 
 
114 
Note. n = 283. * = p < .01. ** = p < .001.  
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Chapter Five: Discussion 
 
HIV-infected women are at increased risk for developing cervical dysplasia and 
cancer as a result of HPV-infection (ACOG, 2010; Tello et al., 2010; Aberg et al., 2009); 
However, HIV-infected women are not receiving Pap testing according to ACOG 
guidelines (Leece et al., 2010). Approximately 25% of HIV-infected women had not 
received their annual Pap smear during the previous year (Rahangdale, Sarnquist, Yavari, 
Blumenthal & Israelski, 2010; Tello et al., 2010; Oster, Sullivan & Blair, 2009; Stein et 
al., 2001; Solomon et al., 1998). Many reasons have been cited to explain poor test 
adherence such as age, race/ethnicity, tobacco use, weight, education, ability to pay, risky 
behaviors, HIV viral load, CD4-lymphocyte count, and perceived susceptibility, 
seriousness, benefits, and barriers. Currently, the literature is lacking a comprehensive 
study evaluating relationships between Pap test adherence and numerous cited variables; 
thus, useful information for clinicians is needed to help them identify women at risk for 
poor adherence to cervical cancer screening. 
The purpose of the study was to evaluate HIV-infected women’s knowledge of 
cervical cancer and HPV, perceived susceptibility to cervical cancer, and their attitudes 
regarding the severity of cervical cancer. Further, the study assessed the women’s 
perceived self-efficacy, benefits, and barriers to cervical cancer screening. In addition, 
predictors of cervical cancer screening in HIV-infected women were evaluated. This 
65 
 
chapter discusses the findings of the study in light of existing literature, states limitations 
and strengths of the study, offers recommendations for future research, and discusses 
implications for practice. The study determined the following: a) the relationships 
between the Health Belief Model subscale variables and Pap smear adherence, b) the 
relationships between the subscale variables and selected demographic factors, and c) the 
ability of the subscale variables and demographic factors to predict Pap smear adherence. 
Results differed based the source of data about on Pap smear (participant-reported versus 
medical chart documented). 
Sample Characteristics 
 The current study had the lowest mean knowledge score (6.02) compared to data 
reported in existing studies (Denny-Smith, Bairan & Page, 2006; Ingledue et al., 2004; 
Montgomery, Bloch, Bhattacharya & Montgomery, 2010). About half (50.3%) of the 
women in the current study reported having a high school diploma, and 33% reported 
having less than a high school education. Three previous studies used the HPV/cervical 
cancer knowledge questionnaire in samples of college women, nursing students and 
women ages 40 – 70 (Denny-Smith, Bairan & Page, 2006; Ingledue et al., 2004; 
Montgomery, Bloch, Bhattacharya & Montgomery, 2010). The highest mean knowledge 
score was in female nursing students (n = 240, M = 10.2, range of 1 -15) (Denny-Smith, 
Bairan & Page, 2006). The majority, 71 – 100 %, of participants in the other studies had 
some college which may account for the difference in knowledge scores. Further studies 
are needed to determine the effect of level of education on health literacy. . 
 Women in the study did not feel susceptible to cervical cancer (M = 9.59, range 4-
20), nor did they think that cervical cancer was serious (M = 20.88, range 7 – 35). 
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Numerous studies have used Champion’s HBM scales to evaluate perceived 
susceptibility and severity to cervical cancer, but for unknown reasons, items were added 
or deleted. Despite the various score ranges, women in earlier studies did not feel they 
were susceptible to cervical cancer (Allahverdipour & Emami, 2008; Boonpongmanee & 
Jittanoon, 2007; Burak & Meyer, 1997; Denny-Smith et al., 2006: Ingledue et al., 2004; 
Montgomery, Bloch, Bhattacharya & Montgomery, 2010; Ho et al., 2005; Park, Chang & 
Chung, 2005). Similar results were documented for perceived severity, except for the 
results of two studies which stated that women agreed or understood that cervical cancer 
was serious, but the questions that measured seriousness were not about the participants’ 
personal perception (Byrd et al., 2004; Guilfoyle et al., 2007). For example, one question 
stated, “cervical cancer is not as serious as other types of cancers” (Byrd et al., 
2004).Further studies are needed to determine the reason for low susceptibility score in 
women infected with HIV. It is possible that HIV-infected feel that they are destined for 
death related to their HIV or are overwhelmed with their HIV diagnosis that are chronic 
diseases seem miniscule. Futures studies may consider determining the effects of 
fatalistic attitudes on Pap smear adherence and perceived susceptibility. 
 In the current study, women perceived that Pap smears were beneficial, (M = 
15.93; range 4 - 20), and the majority of women did not believe they had barriers 
preventing them from getting a Pap smear (M = 29.16, range 14 – 56) (Table 4).  The 
literature supports this finding (Byrd et al., 2004; Ho et al., 2005; Park, Chang & Chung, 
2005). Note that perceived benefits and barriers were not measured using the same 
subscale, but variations of Champion’s HBM.  
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 Women in the study believed that they could request a Pap smear from their 
health provider(s) (M = 40.22, range 10-50). To date, no studies have used Champion’s 
Self-efficacy scale to evaluate cervical cancer screening; therefore, the current literature 
cannot be linked to results of this study. Women receiving care from the Specialty Care 
Clinic may feel comfortable in requesting Pap smears and discussing intimate 
information because providers ask questions at each visit about risky behaviors including 
recent sexual encounters. It is essential for researchers to further study the relationship 
between perceived self-efficacy and Pap smear adherence.  
Aim One 
The purpose of this section was to evaluate the relationship between Pap test 
adherence in women infected with HIV and the following variables: CHBM, CSE, 
HPV/cervical cancer knowledge scale.  There are two outcome variables: participant 
reported last Pap smear during the past year (yes or no) and medical chart documented 
last Pap smear during the past year (yes or no).  
One would expect that women who received their Pap smear during the past year 
would have higher knowledge scores; and perceived susceptibility, seriousness, benefits, 
and self-efficacy scores; and lower perceived barriers scores. Most of the findings from 
the current study did not support that conclusion, but statistically significant differences 
were revealed for perceived barriers and self-efficacy. 
Pap smear. 
Knowledge. Differences in knowledge scores by last reported or documented Pap 
smear were not statistically significant. In the current study, women had knowledge 
deficits regarding HPV and cervical cancer. Future studies may want to consider creating 
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an intervention to increase HPV and cervical cancer knowledge using pre- and post- 
testing to evaluate the impact of the intervention on Pap smear adherence. In the current 
study knowledge was not directly related to Pap smear adherence, but knowledge was 
related to perceived barrier and self-efficacy, which were both related to Pap smear 
adherence.  
Perceived seriousness and susceptibility. Women in the current study did not 
differ in their perceptions regarding the seriousness of cervical cancer and their personal 
susceptibility to cervical cancer based on their last reported or medical chart documented 
Pap smear. The findings are in agreement with previous studies (Allahverdipour & 
Emami, 2008; Boonpongmanee & Jittanoon, 2007; Burak & Meyer, 1997; Denny-Smith 
et al., 2006: Ingledue et al., 2004; Montgomery, Bloch, Bhattacharya & Montgomery, 
2010; Ho et al., 2005; Park, Chang & Chung, 2005). It is possible that perceived 
seriousness to cervical cancer and HPV does not explain Pap smear adherence, but 
perceived susceptibility is a predictor of Pap smear adherence. Therefore, further research 
is needed.  
Perceived benefits. Perceived benefit scores did not differ by last participant-
reported or medical chart documented Pap smear (Tables 4 & 5). The findings of the 
current study do not agree with existing research. The current study is the first to evaluate 
HIV-infected which may account for the variations in the findings between the current 
study and existing studies. Further research regarding factors that influence cervical 
cancer screening should not focus on benefits of cervical cancer screening.  
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Aim Two 
 The purpose of this section was to evaluate the relationships between subscale 
variables (CHBM scale, CSE scale, HPV/cervical cancer knowledge) and selected 
demographic factors in HIV-infected women. To date, there is no published data 
evaluating differences in subscale variables by sociodemographic, risky behavior and 
clinical variables with regard to cervical cancer.  
Sociodemographic.  
Race. Caucasian women in the current study perceived themselves to be more 
susceptible to cervical cancer than Black women. The reason for the finding is unknown, 
but in this study susceptibility was correlated with barriers and seriousness. Further study 
is needed in African American women to determine their understanding of susceptibility 
and their personal risk for cervical cancer. 
Education. In the current study, there are differences in knowledge, perceived 
benefits, barriers and self-efficacy by education (Table 10). As the level of education 
increased, knowledge increased, benefits scores increased, fewer barriers were perceived 
and self-efficacy scores increased. The finding is reasonable because knowledge is 
significantly correlated with self-efficacy, benefits and barrier. According to the current 
study, as knowledge increased benefits and self-efficacy increased and barriers decreased 
(p < .001). Future interventions should focus on increasing knowledge and perceived self-
efficacy of women with a high school education or less.  
Age. As women aged, their knowledge regarding HPV and cervical cancer 
decreased (Table 21); this is an expected finding. In the current study the average age was 
approximately 45 and the mean knowledge scores were low. It should be noted that the 
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first HPV prevention vaccine was approved in 2006 for females ages 9 - 26; therefore, 
older women are not the target of HPV prevention campaigns and may not be as 
knowledgeable as younger women (CDC, 2011). The same rationale can be used for 
older women feeling less susceptible to HPV and cervical cancer. Women over the age of 
26 may not feel susceptible because the vaccine is not recommended for them. Further 
research is needed. 
Risky behavior.  
Cigarette use. Women who reported cigarette use felt more susceptible to cervical 
cancer. Although not statistically significant, they were more knowledgeable about 
cervical cancer and HPV, which is a reasonable finding. Providers are successfully 
conveying to patients that cigarette use increases their risk of cancer.  
Condom use. There is an association between condom and the following subscale 
variables: perceived barriers and HPV knowledge. Perceived barriers and knowledge 
have a negative weak relationship, therefore, it would be expected that women who 
reported using condoms 75% of time would have lower perceived barrier scores than 
women who reported using condoms 100% of the time because the former had higher 
knowledge scores. Several women (165) reported always using condom which could be 
the results of social desirability responses, which increases the possibility of error. 
Clinical variables. 
HIV viral load. Women with low viremia were more confident in their ability to 
request a Pap smear than women with high viremia. Women with low viremia are taking 
antiretroviral medication to suppress HIV, which means that they are more likely to be 
adherent to scheduled appointments and have an establish rapport with their provider(s); 
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therefore increasing their confidence to request services. The relationship between self-
efficacy regarding Pap smear adherence and HIV viral load was explored for the first 
time in the current study. However, existing studies have documented that women with 
lower viremia are more likely to adhere to Pap smears (Baranoski et al., 2011; Tello et 
al., 2010). Further study is needed to explain the relationship between HIV viral load and 
Pap smear adherence.  
Subscale variables. Perceived susceptibility and seriousness were positively 
correlated, but the relationship was weak; so as susceptibility increases severity increases. 
This finding is supported by three studies conducted in women from various backgrounds 
and ages (Allahverdipour & Emami, 2008; Denny-Smith, Bairan & Page, 2006; 
Montgomery, Bloch, Bhattacharya & Montgomery, 2010). Despite the significant 
correlations between perceived susceptibility and seriousness, their relationship to Pap 
smear adherence was not significant, but perceived susceptibility was a significant 
predictor of Pap smear adherence. Therefore, researchers should not focus on perceived 
seriousness in future studies regarding Pap smear adherence. 
There was a negative weak significant relationship between perceived barriers and 
benefits (Table 21). Women who perceived more benefits to cervical cancer screening 
perceived fewer barriers to cervical cancer screening. Existing studies support the finding 
(Allahverdipour & Emami, 2008; Lee, Fogg & Menon, 2008). Further studies should 
examine barriers that prevent women for adhering to Pap smears per ACOG guidelines 
via quantitative or qualitative research.  
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Aim Three 
Aim 3 assessed the ability of the subscale (CHBM and CSE, and knowledge) and 
select demographic variables to predict Pap testing in women infected with HIV. 
Perceived susceptibility, barriers and last CD4+ T lymphocyte count predicted last Pap 
smear (Table 22). The variables did not predict medical chart documented Pap smear 
(Table 23).  
In the current study, variables entered to the equation did not predict medical 
chart documented Pap smear (Table 23). Frequently providers request records from other 
facilities and upon receipt the records are lost, misplaced, or not enter into the electronic 
medical record system, which would result in women being incorrectly labeled as not 
having a Pap smear during the past year. A retrospective chart review study conducted at 
Johns Hopkins HIV clinic revealed that age, CD4+ T lymphocyte count and illicit 
substance use were predictors of Pap smear adherence (Tello et al., 2010). The study 
included approximately 1,100 participants receiving care from a clinic that provided 
gynecological and primary services in the same building which may improve 
documentation of last Pap smear. More HIV providers and clinics may want to consider 
offering multiple services in one building to increase adherence.   
The current study revealed that perceived barriers and last CD4+ T lymphoctyte 
count are significant predictors of participant-reported last Pap smear when they are the 
only two variables retained in the equation. Existing research supports the currents 
study’s finding that perceived barriers is a significant predictor of Pap testing 
(Boonpongmanee & Jittanoon, 2007; Allahverdipour & Emami, 2008; Lee, Fogg, & 
Menon, 2008; Ho et al., 2005). In addition, perceived susceptibility was a significant 
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predictor of participant-reported last Pap smear only in the presence of perceived 
barriers, age and knowing that a family history of cervical cancer is a risk factor for 
cervical cancer. There was a significant, weak relationship between perceived 
susceptibility and age, and perceived susceptibility and barriers which is a potential 
reason for perceived susceptibility being a significant predictor of participant-reported 
last Pap smear which is a potential reason for the findings.  
Cronbach’s Alpha 
Cronbach’s alpha was calculated for measures used in the study to evaluate the 
reliability of each subscale (Table 24). Overall the subscales had good internal 
consistency except perceived benefits. The perceived benefits subscale had acceptable 
internal consistency (α = .72). A Cronbach’s alpha of .72 is acceptable, but the goal for a 
seasoned scale is .80 or higher (Gliem & Gliem, 2003). Removing item 31 would 
increase Cronbach’s alpha from .72 to .75. The perceived benefits scale for the current 
study was revised to reflect cervical cancer, rather than breast cancer. Victoria Champion 
created the scale in 1984 for breast self-examination (Champion, 1984). Gulten, Akyuz 
and Acikel (2010) adapted CHBM scales for cervical cancer and Pap smear testing, but 
instead of the perceived benefits scale consisting of four items the adapted scale consisted 
of seven. Four of the seven items measured benefits perceived and health motivations. It 
should be noted that health motivation is a separate concept developed by Victoria 
Champion (1984). For the current study only the four items that measure perceived 
benefits were retained. Cronbach’s alpha is influenced by the number of items in the 
scale. It is possible that shortening the scale weakened it; therefore, utilization of the 
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subscale perceived benefits subscale for cervical cancer in the current study is novel and 
further research is needed to determine the reliability of the subscale.  
Strengths 
 The current study is novel in that it evaluates Pap test adherence in HIV-infected 
women using the HBM more specifically the adapted CHBM and CSE scales. The 
current study utilized more variables from the HBM to assess Pap smear adherence than 
the existing body of literature. CHBM and CSE scales were adapted for use in cervical 
cancer by a researcher in Turkey, so the current study is the first in the U.S.A to utilize 
the adapted scale. The current study contributes to the current body of literature. 
Limitations 
 The study has several limitations in its design and sampling; therefore, the 
generalizability of the findings may be limited. The study used a sample of convenience 
selected from two local ambulatory specialty care clinics, which may introduce selection 
bias. The participants were currently in care which excluded women who are potentially 
at greater risk due to lack of care. Future studies should include women not receiving 
regular care. The survey consisted of 76 items delivered via paper, which could lead 
participants to become fatigued and randomly select answers, which could increase error 
variance. Women may have selected answers that were socially desirable, which could 
result in bias. There are other clinics that serve HIV-infected women, but only women at 
the two research sites were eligible to participate.  
Implications for Nursing  
 Practice. Health care providers should provide women with accurate and detailed 
information regarding HPV, cervical cancer, and Pap smears. This is particularly 
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important for women infected with HIV. Women should continue to be encouraged to 
obtain Pap smears per current guidelines. Barriers to Pap smear adherence should be 
addressed and eliminated or minimized when possible. Providers may want to consider 
completing Pap smears during a scheduled follow-up visit and not scheduling a separate 
gynecology appointment. Women had some knowledge deficits about HPV and cervical 
cancer; therefore educational material regarding HPV, cervical cancer and Pap smears 
should be available in various formats such as printed and audiovisual. Providers should 
complete educational activities to increase their awareness and knowledge. Having a 
better understanding can lead providers to be better advocates for Pap smears. 
Technology is a big part of healthcare so providers can search for a system that alerts 
them when patients’ Pap smears are due. 
  Research. Participants in the current study had knowledge deficits regarding 
HPV and cervical cancer and a poor understanding of the Pap smear procedure. 
Knowledge deficits in patients could be a reflection of knowledge deficits in providers. 
Future studies should focus on assessing healthcare providers’ knowledge of cervical 
cancer, HPV, and current ACOG guidelines. Existing research has linked inadequate 
health literacy to knowledge deficit (Gazmararian, Williams, Peel & Baker, 2003; 
William, Baker, Parker & Nurss, 1998). Understanding health information, including labs 
such as CD4+ T lymphocytes count and HIV viral load, may lead patients to make better 
health-related decisions. Therefore, Researchers should evaluate the effects of health 
literacy and numeracy on HPV/ cervical cancer knowledge in HIV-infected women.  
In the current study, women with more confidence in their ability to request a Pap 
smear were more likely to have had a Pap smear within the past year, and perceived 
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susceptibility, barriers and last CD4+ T lymphocyte count were predictors of Pap smear 
adherence, and women lacked knowledge of HPV and cervical cancer. Due to high 
internal consistency of the perceived self-efficacy scale, the current instruments should be 
used in socially diverse population. Future interventions should focus in decreasing 
barriers, increasing adherence to antiretroviral medications to increase CD4+ T 
lymphocyte counts and increasing women’s perceived risk of developing cervical cancer. 
Since women lacked knowledge, future studies could focus on how HIV-infected women 
receive health-related information. Qualitative research is vital in understanding factors 
that influence cervical cancer screening in HIV-infected women. 
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who choose to take part. This document is called an informed consent form. Please read 
this information carefully and take your time making your decision. Ask the researcher to 
discuss this consent form with you, please ask her to explain any words or information 
you do not clearly understand.   
Please tell the research study investigator if you are taking part in another research study. 
We are asking you to take part in a research study called: Predicting Factors that 
Influence Cervical Cancer Screening in HIV-Infected Women: Using the Health Belief 
Model 
The person who is in charge of this research study is Crystal Chapman Lambert.   
 
The research will be conducted at Bartow Specialty Care Clinic and Hillsborough County 
Specialty Care Clinic via a survey. 
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Purpose of the study 
• The purpose of this study is to learn more about HIV-infected women’s 
knowledge and perception of cervical cancer and cervical cancer screening. 
• As a women infected with HIV, you can provide information that can be used in 
the future development of programs to increase cervical cancer awareness and 
cervical cancer screening. 
• A PhD student attending USF College of Nursing is conducting the study for the 
purpose of a dissertation. 
Study Procedures 
If you take part in this study, you will be asked to provide: 
• Information about your medical history and sexual history, and complete a pencil 
and paper survey regarding your perceptions and knowledge about cervical cancer 
and cervical cancer screening.  
This study can be completed during one sitting and is expected to take less than 60 
minutes. 
The study will be conducted at Bartow Specialty Care Clinic and Hillsborough County 
Specialty Care Clinic and the survey can be completed in a private area.  
Total Number of Participants 
It is expected that 300 women will volunteer in this study at Bartow Specialty Care Clinic 
and Hillsborough County Specialty Care Clinic.  
Alternatives 
You do not have to participate in this research study. 
Benefits 
We are unsure if you will receive any benefits by taking part in this research study.   
Risks or Discomfort 
This research is considered minimal risk.  That means that the risks associated with this 
study are the same as what you face every day.  There are no known additional risks to 
those who take part in this study. 
Compensation 
You will be given a $15 Walmart gift card after completing the survey.   
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Cost 
There will be no additional costs to you as a result of being in this study.  However, 
routine medical care for your condition (care you would have received whether or not 
you were in this study) will be charged to you or your insurance company.   
Privacy and Confidentiality 
We will keep your study records private and confidential.  Certain people may need to 
see your study records.  By law, anyone who looks at your records must keep them 
completely confidential.  The only people who will be allowed to see these records are: 
The research team, including the Principal Investigator, study coordinator, research 
nurses, and all other research staff. 
Certain government and university people who need to know more about the study.  
For example, individuals who provide oversight on this study may need to look at 
your records. This is done to make sure that we are doing the study in the right 
way.  They also need to make sure that we are protecting your rights and your 
safety. 
Any agency of the federal, state, or local government that regulates this research.  
This includes the Food and Drug Administration (FDA), Florida Department of 
Health (FDOH), FDOH Institutional Review Board and the Department of Health 
and Human Services (DHHS) and the Office for Human Research Protection 
(OHRP). 
The USF Institutional Review Board (IRB) and its related staff, who have oversight 
responsibilities for this study, staff in the USF Office of Research and Innovation, 
USF Division of Research Integrity and Compliance, and other USF offices who 
oversee this research. 
We may publish what we learn from this study.  If we do, we will not include your name.  
We will not publish anything that would let people know who you are.   
Voluntary Participation / Withdrawal 
You should only take part in this study if you want to volunteer.  You should not feel that 
there is any pressure to take part in the study.  You are free to participate in this research 
or withdraw at any time.  There will be no penalty or loss of benefits you are entitled to 
receive if you stop taking part in this study 
New information about the study 
During the course of this study, we may find more information that could be important to 
you.  This includes information that, once learned, might cause you to change your mind 
about being in the study.  We will notify you as soon as possible if such information 
becomes available. 
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You can get the answers to your questions, concerns, or complaints  
If you have any questions, concerns or complaints about this study, or experience an 
adverse event or unanticipated problem, call Mrs. Crystal Chapman Lambert  by email at 
cchapman@health.usf.edu. 
Call Florida Department of Health Institutional Review Board (DOH IRB) at (866) 433-
2775 (toll free in Florida) or 850-245-4585 If: 1) you have questions about your rights as 
a participant in this study, general questions, or have complaints, concerns or issues you 
want to discuss with someone outside the research or 2) If you have questions about your 
rights as a person taking part in this research study. 
Statement of Person Obtaining Informed Consent 
I have carefully explained to the person taking part in the study what he or she can expect 
from their participation. I hereby certify that when this person signs this form, to the best 
of my knowledge, he/ she understands: 
• What the study is about; 
• What procedures/interventions/investigational drugs or devices will be used; 
• What the potential benefits might be; and 
• What the known risks might be. 
 
I can confirm that this research subject speaks the language that was used to explain this 
research and is receiving an informed consent form in the appropriate language. 
Additionally, this subject reads well enough to understand this document or, if not, this 
person is able to hear and understand when the form is read to him or her. This subject 
does not have a medical/psychological problem that would compromise comprehension 
and therefore makes it hard to understand what is being explained and can, therefore, give 
legally effective informed consent. This subject is not under any type of anesthesia or 
analgesic that may cloud their judgment or make it hard to understand what is being 
explained and, therefore, can be considered competent to give informed consent.   
 
 
 
 
______________________________________________________________________ 
Signature of Person Obtaining Informed Consent / Research Authorization Date 
 
_______________________________________________________________ 
Printed Name of Person Obtaining Informed Consent / Research Authorization 
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Appendix C: Participant Questionnaire 
 
1. Age (Please write a number. Do NOT write your date of birth) ___ 
 
2. Race/Ethnicity 
a. Black/African American  
b. White  
 
3. Ethnicity 
a. African American (non-Hispanic)   
b. Caribbean (non-Hispanic)   
c. Hispanic/Latina 
d.  Other  
Please indicate ethnicity of you would like. ______________________ 
 
4. Marital Status 
a. Single 
b. Significant other 
c. Married 
d. Divorced 
e. Widowed 
 
5. Primary Language  
a. English 
b. Creole 
c. Spanish 
d. Other 
 
6. Educational Level: 
a. Less than a high school diploma 
b. High school/trade school 
c. College 
 
7. Cigarette use 
a. Yes 
b. No 
8. If yes: 
a. Currently 
b. Formerly 
 
90 
 
Appendix C (Continued) 
 
 
9. Substance use (Cocaine, crystal-meth, or heroin) 
a. Yes 
b. No 
 
10. If yes: 
c. Currently 
d. Formerly 
 
11. How often do you use condoms? 
a. Never 
b. 25% 
c. 50% 
d. 75% 
e. 100% 
f. I don’t want to answer 
 
12. Number of sexual partner during past year? 
a. 0 
b. 1 
c. 2 or more 
d. I don’t want to answer 
 
13. Sexual experience: 
a. Currently sexually active (during the past 12 months) 
b. Not currently active 
c. Never had sexual intercourse 
 
14. Have you ever had a Pap test? 
a. Yes 
b. No 
 
15. If yes, when was your last Pap test? 
a. Within the past year 
b. Within the past 2 years 
c. Greater than 2 years 
 
16. Have you ever been told that your Pap results were abnormal? 
a. Yes 
b. No 
17. Do you feel like your doctor or nurse practitioner treats you differently because of 
your race or ethnicity? 
a. Yes 
b. No  
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18. Do you feel like your doctor or nurse practitioner treats you differently because of 
your HIV/AIDS status? 
a. Yes 
b. No 
 
For question 19- 57, please circle: Strongly disagree, Disagree, Neutral, Agree, or 
Strongly agree. 
Susceptibility 
19. It is likely that I will get cervical cancer in the future. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
20. There is a good possibility I will get cervical cancer in the next 10 years. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
21. I feel I will get cervical cancer in the future. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
22. I am more likely than the average woman to get cervical cancer.  
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
Seriousness 
23. The thought of cervical cancer scares me 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
24. When I think about cervical cancer, my heart beats faster  
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
25. I am afraid to think about cervical cancer  
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
26. Problems I would experience with cervical cancer would last a long time 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
27. Cervical cancer would threaten a relationship with my boyfriend, husband, or 
partner. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
28. If I had cervical cancer my whole life would change 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
29. If I developed cervical cancer, I would not live longer than 5 years 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
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Benefits 
30. Having regular Pap Smear Tests will help to find changes to the cervix, before 
they turn into cancer. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
31. If cervical cancer was found at a regular Pap Smear Test its treatment would not 
be so bad. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
32. I think that having a regular Pap Smear Test is the best way for cervical cancer to 
be diagnosed early. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
33. Having regular Pap Smear Tests will decrease my chances of dying from cervical 
cancer. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
Barriers 
34. I am afraid to have a Pap Smear Test for fear of a bad result. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
35. I am afraid to have a Pap Smear Test because I don’t know what will happen. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
36. I don’t know where to go for a Pap Smear Test. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
37. I would be ashamed to lie on a gynecologic examination table and show my 
private parts to have a Pap Smear Test. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
38. Having a Pap Smear Test takes too much time. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
39. Having a Pap Smear Test is too painful.  
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
40. Health professionals doing Pap Smear Test are rude to women. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
41. I neglect or cannot remember to have a Pap Smear Test regularly. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
42. I have other problems more important than having a Pap Smear Test in my life. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
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43. I am too old to have a Pap Smear Test regularly. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
44. There is no health center close to my house to have a Pap Smear Test. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
45. If there is cervical cancer development in my destiny, having a Pap Smear Test 
cannot prevent it. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
46. I prefer a female doctor to conduct a Pap smear. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
47. I will never have a Pap smear if I have to pay for it. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
Perceived Self-efficacy 
48. I can arrange transportation to get to my Pap smear appointment. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
49. I can arrange things in my life to have a Pap smear. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
50. I can talk to people at the clinic about my concerns. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
51. I can get a Pap smear even if I am worried. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
52. I can get a Pap smear even if I don’t know what to expect. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
53. I can find a way to pay for my Pap smear. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
54. I can make an appointment for a Pap smear. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
55. I know for sure that I can get a Pap smear if I really want to. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
56. I know how to go about getting a Pap smear. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
 
94 
 
Appendix C (Continued) 
 
57. I can find a place to get a Pap smear. 
Strongly disagree Disagree Neutral  Agree           Strongly agree. 
For questions 58- 63, please select the best answer. 
Knowledge  
58. The virus associated with cervical cancer is transmitted by:  
a. Sexual intercourse 
b. Blood transfusions 
c. Inanimate objects 
d. Talking 
e. I don’t know 
 
59. Cervical cancer and pre-cancer cells are associated with the presence of:  
a. Epstein-Barr virus 
b. Ebola virus 
c. Human papillomavirus 
d. Human immunodeficiency virus  
d. I don’t know 
 
60. Cervical dysplasia (abnormal cells) can be detected (found) by:  
a. X-rays  
b. Pap tests 
c. Blood tests 
d. Urine 
e. I don’t know 
 
61. Prevention of cervical cancer may require:  
a. Delayed onset of sexual activity 
b. Annual Pap test  
c. Use of condoms 
d. All of the above 
e. I don’t know 
 
62. Human papillomavirus (HPV) can cause: 
 a. Vaginal discharge 
 b. Genital warts 
 c. Itching 
 d. Burning urination 
 e. I don’t know 
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63. HPV can live in the skin without causing growths or changes: 
 a. Yes 
 b. No 
 c. I don’t know 
 
For questions 64 – 72, please identify which of the following are risk factors of 
cervical cancer: (Answers: yes or no) 
 
64. Multiple sex partners 
a. Yes  
b. No 
 
65. Having genital warts/HPV 
a. Yes 
b. No 
 
66. Sexual intercourse before age 18 
a. Yes 
b. No 
 
67. Being immune suppressed 
a. Yes 
b. No 
 
68. Having Chlamydia 
a. Yes 
b. No 
 
69. Smoking cigarettes 
a. Yes 
b. No 
 
70. Poor diet (low in fruits and vegetables) 
a. Yes 
b. No 
 
71. Family history of cervical cancer 
a. Yes 
b. No 
 
72. Use of oral contraceptives (birth control) 
a. Yes 
b. No 
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73. Did your doctor or nurse practitioner at this clinic encourage you to get a Pap 
smear? 
a. Yes 
b. No 
 
74. Did your doctor or nurse practitioner at a different clinic encourage you to get a 
Pap smear? 
a. Yes 
b. No 
 
75. What or who encouraged you to get a Pap smear? 
Please list your reason(s): 
__________________________________________________________________ 
 
76. What prevented you from getting a Pap smear? 
Please list your reason(s): 
__________________________________________________________________ 
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Appendix D: Chart Review 
 
77. Year of HIV diagnosis _____ 
 
78. Year of AIDS diagnosis _____ 
 
79. Patient status 
a. New  
b. Existing (old) 
 
80. CD4 count _______ 
 
81. Viral load 
a. Undetectable 
b. Not undetectable 
 
82. History of a hysterectomy 
a. Yes 
b. No 
 
83. Height ______ 
 
84. Weight  ______ 
 
85. Last Pap smear history _____ 
 
86. History of abnormal Pap test? 
a. Yes  
b. No 
 
87. History of depression? 
a. Yes 
b. No 
 
